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ABSTRACT 
As part of an effort to develop an ocular insert controlled drug 
release system to treat Bovine Infectious Keratoconjunctivitis, tests 
were performed on hydrogel disks containing the antibiotic, tylosin 
tartrate. Thin layer chromatography was utilized to characterize the 
rates of release, and microstructural information from scanning electron 
microscopy was of use in determining ways to improve the release 
characteristics. 
Disk-shaped laminates of 90:10 methyl methacrylate/2-hydroxyethyl 
methacrylate which contained tylosin tartrate were studied for release 
characteristics by a five-day in vitro (in mammalian Ringer's solution 
at 37°C) experiment. Three different drug loading configurations were 
compared in quintuplicate: poly (lactic acid)-tylosin tartrate matrix 
containing 4.8 mg of antibiotic in the center of the disk, S.O mg of 
tylosin tartrate powder in the center of the disk, and so.a mg of 
tylosin tartrate powder in the center of the disk. On the basis of 
known minimum inhibitory concentration levels for the bacteria of 
interest and known tear flow rates, a minimum release rate range of 
1. 2-2. S ug/hr of tylosin tartrate was required. Release rates of 
approximately 20-30 ug/hr were observed for the controlled-release disks 
containing SO.a mg of tylosin tartrate. Release rates for the other two 
systems were lower than. 1.2 ug/hr. 
Thin layer chromatography and direct densitometric scanning were 
utilized to quantitate the amount of tylosin tartrate in release-
experiment samples. The variability of the quantitative analysis and 
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the linearity of the relationship between average weight of peak and 
tylosin tartrate amount were determined by a statistical analysis of 
type-one aqueous and saline solution standards with tylosin tartrate 
concentrations of 0.1-10.0 ug/10.0 ul. A sensitivity of 0.2 ug of 
tylosin tartrate was achieved. Type-one aqueous solutions produced 
coefficients of variance from 10.0-28.6 percent for 0.2-0.8 ug amounts 
and 5.6-10.5 percent for 0.9-10.0 ug amounts. Coefficient of 
determination calculations indicated a good linear relationship between 
average weight of peak and tylosin tartrate amount. The reduced 
viscosity of saline solutions resulted in coefficients of variance that 
were inversely related to the saline concentration, and larger than the 
values for type-one aqueous solutions. 
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INTRODUCTION 
Statement of the Problem 
Bovine Infectious Keratoconjunctivitis (BIK) is an acute contagious 
ophthalmia characterized by lacrimation, photophobia, corneal ulcers, 
and corneal opacities. BIK affects cattle worldwide. The disease is 
rarely fatal, but infected cattle refuse food. Consequently, major 
economic loss may occur as milk production, body weight, and growth 
diminish. 
The principal treatment method consists of topical applications of 
antibiotic and sulfonamide eyedrops, sprays, powders, or ointments for a 
period of five to seven days. Lachrymal fluid rapidly removes drug from 
the eye; therefore, trea'tment is effective when medication is applied 
two or three times daily. This repetitious reg.imen is timecconsuming 
and costly; therefore, developing a more efficient method of drug 
administration is of interest. 
To address the BIK treatment problem, a controlled drug release 
system was developed and characterized for its suitability for this 
application. Controlled-release systems may utilize biocompatible 
polymers to regulate the duration and rate of drug release for extended 
periods of time. An ocular controlled-release system that maintains a 
therapeutic level of a drug currently employed to treat BIK would 
eliminate the repetitious regimen. In this study, hydrogels were 
selected as the polymer for the ocular controlled-release system. 
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Certain hydrogel formulations are widely utilized as soft-contact lenses 
and have controllable water-imbibing characteristics. Tylosin tartrate, 
an agricultural antibiotic that effectively eradicates causative and 
contributory organisms of BIK, was chosen as the treatment drug. 
An acceptable ocular controlled-release system of hydrogel and 
tylosin tartrate would release sufficient (microgram) quantities of drug 
per hour into low volumes of lachrymal fluid in the animal's eyes. An 
important part of the research to be reported was to develop a method to 
characterize samples representing amounts of tylosin tartrate released 
into artificial lachrymal fluid. A method based on thin layer 
chromatography was developed and applied to quantitate tylosin tartrate 
release as a function of time from three types of hydrogel-drug disks. 
The hydrogel-drug disk experiments were used to examine effects of 
differences in drug loading and the potential usefulness of a poly 
(lactic acid) matrix containing the drug as a type of reservoir within 
the hydrogel disk. These experiments were directed at evaluating the 
feasibility of using hydrogel ocular inserts to release a suitable 
antibiotic for treatment of BIK. 
Literature Review 
Nomenclature 
BIK is commonly called pinkeye. The disease is also referred to as 
Infectious Bovine Keratoconjunctivitis IBK (Hughes and Pugh, 1970; 
Hughes and Pugh, 1975; Hughes, 1981), Infectious Bovine Kerato-
Conjunctivitis (Thrift and Overfield, 1974), Bovine Infectious 
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Keratoconjunctivitis BIK (Pugh and Hughes, 1975; Jensen and Mackey, 
1979; Blogg, 1980), and Bovine Infectious Keratitis (Baldwin, 1945). 
Other synonyms are infectious ophthalmia, and keratitis solaris (Hughes, 
1981). 
Etiology and modes of transmission 
Moraxella bovis, a common agricultural bacteria (Hughes and Pugh, 
1975), is capable of living through the winter (Blogg, 1980). Various 
strains have been identified, and the characteristics of Moraxella bovis 
strains associated with BIK are listed in Table 1. 
TABLE 1. Characteristics of Moraxella bovis strains associated with 
Bovine Infectious Keratoconjunctivitis. (Pugh, 19&9). 
A. Gram-negative, nonmotile diplobacillus. 
B. Usually hemolytic, smooth, circular colonies with an entire edge 
convex to umbonate, grayish white and slightly indented into the 
medium., 
c. Does not reduce nitrates to nitrites or, ferment carbohydrates. 
D. Are proteolytic, oxidase positive, and produce a typical three-
zone reaction when grown in litmus milk. 
E. Produce no surface growth in liquid medium but develop a coarse, 
flocculent sediment with little turbidity. 
F. Do not grow in Herellea agar. 
G. Produce firm easily fragmented colonies which autoagglutinate when 
placed in most liquid mediums. 
Moraxella bovis dissociates into various forms. The rough colony 
type is avirulent, while the smooth colony (typical type) of Moraxella 
bovis induces Bovine Infectious Keratoconjunctivitis (Jackson, 1953). 
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Moraxela bovis interconverts between its hemolytic and nonhemolytic 
forms with exposure to ultraviolet light (Pugh, 1969; Pugh and Hughes, 
1968). The virulent form is the primary infectious agent of BIK (Pugh 
and Hughes, 1968; Hughes and Pugh, 1970). 
Mycoplasma bovoculi is the primary causative agent of Mycoplasmal 
Conjunctivitis, a different disease than BIK; however, Mycoplasma 
bovoculi may create a more suitable environment for Moraxella bovis 
(Rosenbusch and Knudtson, 1980; Rosenbusch, 1983). The Bovine 
Infectious Rhinotracheitis virus causes conjunctivitis, but not 
keratitis; the inflammed membranes are conducive to the growth of 
Moraxella bovis {Blogg, 1980; Blood and Henderson, 1979). 
Symptoms of the naturally occurring disease are more severe than 
those of the experimentally induced disease; therefore, environmental 
conditions are a factor. BIK is most prevalent during summer and , 
autumn, but severe outbreaks occur in winter when cattle are confined in 
barns and feedlots. Ultraviolet light from the sun induces the 
conversion of nonhemolytic forms of Moraxella bovis to hemolytic forms. 
Face flies (Musca autumnalis and Musca domestica), dust, and temperature 
extremes increase the severity of the disease by irritating the eye 
(Blood and Henderson, 1979; Jensen and Mackey, 1965). 
The exact method of natural transmission has not been determined, 
but the disease can be produced by transferring Moraxella bovis into the 
conjunctiva of the eye (Pugh and Hughes, 1975). A cow may carry 
Moraxella bovis in tear and nasal secretions for one year after having 
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BIK without displaying visible signs of the disease (Blood and 
Henderson, 1979; Blogg, 1980). Tear and nasal secretions are 
transferred by direct contact between cattle, or by intermediaries such 
as wind-blown dust, animal handlers, and face flies (Blogg, 1980). 
Handlers pass Moraxella bovis, but do not contract pinkeye. Face 
flies harbor Moraxella bovis for up to three days after contact with an 
infected eye. A high density of cattle in feedlots facilitates the 
transmission process (Blood and Henderson, 1979). 
Nature of Bovine Infectious Keratoconjunctivitis 
BIK occurs as a unilateral or bilateral infection. After an 
incubation period of one to twenty days, the conjunctiva of the infected 
eye begins to swell and excess tearing occurs. Muscular spasms of the 
eyelid.and an elevated temperature are common. Ambient light causes 
pain; therefore, the animal seeks out dark areas, closes the eye, and 
refrains from eating (Blogg, 1980). Range cattle have died from 
starvation, drowning, and falling from high places due to impaired sight 
(Baldwin, 1945). 
Three to four days after the initial clinical signs, the eye 
remains tightly closed. A pus discharge mats the fur and causes dirt to 
adhere to the eye region. When the eye is forced open, an opaque 
covering of the cornea is· visible. At this stage, some mild cases of 
BIK begin to recover spontaneously; however, if secondary bacteria enter 
the conjunctiva, corneal ulcers develop. The ulcers invade the interior 
of the eye and cause temporary or permanent blindness. In rare cases, 
ulcers cause fatal meningitis (Jensen and Mackey, 1965). 
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With treatment, cattle that have not developed corneal ulcers 
recover in two to three weeks (Blogg, 1980). Cases that involve severe 
ulceration require five to six weeks for recovery, and permanent corneal 
scars are common (Jensen and Mackey, 1965). Cattle that contract BIR 
seem to develop an immunity against reinfection. A severe case imparts 
greater immunity than a mild case (Blood and Henderson, 1979; Blogg, 
1980). 
The effect of BIR is breed dependent. Cattle with non-pigmented 
eyelids are more susceptible and experience more serious reactions than 
those with pigmented eyelids (Blogg, 1980; Jensen and Mackey, 1965). 
Figure 1 illustrates the relationship between body-color pattern and BIR 
occurrence in the calves of a purbred Hereford herd and a mixed-bree.d 
herd. 
In any particular breed, cattle under two years of age have the 
highest rate of infection and disease. A five-year study conducted at 
the Iowa State University Beef Nutrition Farm found that calves had an 
average annual Moraxella bovis infection rate of seventy-five percent 
and an average annual BIR rate of fifty-eight percent, while cows had an 
average annual Moraxella bovis infection rate of sixty-three percent and 
an average annual BIR rate of sixteen percent (Hughes and Pugh, 1970). 
In a similar study, 158 Hereford calves were observed from birth 
until one year of age. Thir~y-six percent of the bulls and twelve 
percent of the heifers developed BIR. At 205 days of age, the bulls 
that contracted BIR were an average of thirty-six pounds lighter than 
those without BIR. Since the bulls experienced a greater percentage of 
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FIGURE 1. The relationship between body-color and Infectious Bovine 
Keratoconjunctivitis in the calves of a purebred Hereford 
herd and a mixed-breed herd. (Pugh et al., 1982) 
BIK than the heifers, the bulls may be more susceptible to the disease 
or they may simply have an increased chance of being infected due to 
their tendency to roam throughout the herd. At one year of age, the 
calves were reevaluated to determine prolonged effects. The bulls that 
contracted BIK weighed an average of seventy pounds less than those 
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without BIK; however, the heifers had no significant weight difference 
(Thrift and Overfield, 1974). 
A study with dairy cows found that milk production dropped an 
average of twenty-five percent during the course of the disease 
(Baldwin, 1945). 
There is a general lack of information concerning BIK's effect on 
adult bulls because a number of bulls are not routinely maintained in a 
herd. Current research indicates that a bull's libido may be reduced 
while infected with BIK (Thrift and Overfield, 19~4). 
Present methods of treatment 
Early cases of BIK are treated with antibiotic solutions and 
ophthalmic ointments containing chloramphenicol, oxytetracycline, 
penicillin-streptomycin (Jensen and Mackey, 1979; Blood and Henderson, 
1979), or tylosin (Burger, 1970; Rossoff, 1974). Eyedrops are the 
prevalent form of ocular delivery and generally the least expensive. 
Most eyedrops have an aqueous medium; however, poly (ethylene glycol), 
poly (vinyl alcohol), hydroxypropylmethylcellulose, and poly (vinyl-
pyrrolidone) are frequently added to increase viscosity (Chiou and 
Watanabe, 1982). Eighty percent of an eyedrop is lost from the 
preocular film immediately after instillation (Gelatt et al., 1979). 
Ointments that contain a lanolin, petrolatum, or vegetable oil base are 
utilized with drugs such as the tetracyclines. The base increases the 
pentration of drug through the corneal"membrane by improving retention" 
time (Chiou and Watanabe, 1982). Applications to both the upper and 
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lower conjunctival sac, three times daily, for five to seven days 
provides optimum results (Blood and Henderson, 1979; Jensen and Mackey, 
1965),. 
al., 1968), applied twice daily as a 50 mg/ml aqueous spray, eliminated 
clinical signs of BIK and Moraxella bovis from the eyes of cattle after 
five days (Ellis and Barnes, 1961). Sprays have retention times 
comparable to eyedrops. The delivery device increases unit price; 
however, a spray is less irritating than a drop, and less manual 
dexterity is required for proper application (Chiou and Watanabe, 1982). 
® Sampson and Gregory (1974) have shown Tylan plus neomyc.in eye 
powderl to be effective in the treatment of BIK when applied once or 
twice daily for a duration of one to three days. Aronson et al. (1983) 
recommend daily applications of Tylan® plus neomycin eye powder for a 
seven day period to treat BIK. Retention time is similar to the other 
methods. 
Parenteral treatment using sulphadimidine (100 mg/kg body weight) 
provides a therapeutic level in the tears for twelve to twenty-four 
hours (Blood and Henderson, 1979). Oxytetracycline and tylosin used in 
the same manner have also eliminated Moraxella bovis ocular infections 
(Hughes, 1981). Since systemically administered drugs must cross the 
blood-eye barrier, topical instillation is prefe'rred in most situations 
(Chiou and Watanabe, 1982). 
1 Elanco Products Co., Indianapolis, Indiana. 
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When corneal swelling of blood vessels is severe, sub-bulbar 
·conj.unctival injections of corticosteroids and antibiotics together with 
topical anesthetics and atropine improve drug absorption, reduce 
muscular spasms, and minimize drug loss (Blogg, 1980). Blood and 
Henderson (1979) recommend a 1 mg dexamethasone/2 ml mixture of 
penicillin-streptomycin injection; one injection is usually sufficient, 
but some cases'require daily injections for three days. Injections are 
recommended only for antimicrobial drugs such as penicillins, 
cephalosporins, and aminoglycosides, or for application to the eye's 
posterior region. Topically administered drugs diffuse into the 
circulation and Schlemm's Canal before reaching the posterior region 
(Chiou and Watanabe, 1982). Sewing the third eyelid across the globe 
promotes healing and protects against dirt and insects (Jensen and 
Mackey, 1965; Blood and Henderson, 1979; Blogg, 1980). 
Once ulceration occurs, corticosteriods and cortisone drugs are 
replaced by anticollogenases (Blogg, 1980). 
Researchers have tried to develop a BIK vaccine since 1975. A 
vaccine has been developed for protection against a homologous infection 
of Moraxella bovis; however, several strains of Moraxella bovis are 
'' --- ---
present in any infection. Until a vaccine is developed that provides 
protection against the heterologous challenge, other types of treatment 
must be utilized (Pugh et al., 1978; Pugh et al., 1982). 
Theodorakis et al. (1983) developed a poly (lactic acid)-
chloramphenicol sodium succinate ocular insert matrix designed to.treat 
BIK. The insert was attached to the outer side of the third eyelid by 
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sutures or a spear, and released a therapeutic level of chloramphenicol 
sodium succinate for two days at an irregular decreasing rate that did 
not follow the square root of time law (rate proportional tot-~). 
Ocular drug delivery methods 
Present methods of ocular drug delivery are summarized in Table 2. 
A brief comparison of eyedrops, ointments, sprays, powders, oral 
administrations, injections, and inserts was presented in the previous 
section. This section will provide more specific details for contact 
lenses and ocular inserts which bear on the projected application. 
TABLE 2. Methods of ocular drug delivery. (Chiou and Watanabe, 198Z) 
Eye drops 
Ointments 
Sprays 
Powders 
Oral Administrations 
Injections 
Soft Contact Lenses 
Perfusion Systems 
Inserts 
Soft contact lenses, .Bionite2 (soaked in a drug solution), improve 
retention time significantly compared with previous methods and are 
currently utilized in human medicine (Podos et al., 1972). A 
hydrophilic contact lens soaked in a four percent pilocarpine nitrate 
2 Griffin Laboratories Inc., Buffalo, New York. 
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solution releases approximately two-thirds of the drug in five minutes 
' 
(Richardson, 1975). Although the drug concentration rapidly decreases 
and the release mechanism is considered uncontrolled, the effects of 
pilocarpine (Gelatt et al., 1979} and tetracycline (Maichuk, 1975b} are 
seen twenty-four hours after application. In addition to not 
maintaining therapeutic levels for the duration necessary for BIK 
treatment, Hughes and Pugh (1975) found that the nictitating membrane 
removed such devices from the bovine eye within two hours. 
The perfusion system pumps a continuous and constant flow of drug· 
solution to the eye through a poly (ethylene) tube inserted into the 
conjunctiva! sac. Due to its cumbersome nature and expense, it is not 
widely utilized (Chiou and Watanabe, 1982). 
Ocular inserts for use in human medicine are fabricated from 
insoluble or soluble polymers and placed in the.upper or lower 
conjunctiva! sac. The inserts are generally eight to ten millimeter 
diameter circular flat disks, or eight by four millimeter oyal flat 
disks (Refojo, 1974).- Three types of inserts have been studied and are 
currently utilized. 
Soluble inserts of methylcellulose, hydroxypropylcellulose, poly 
(vinyl alcohol), poly (vinyl pyrrolidone), and poly (ethylene glycol) 
deliver a flow of polymer to thicken and stablize the precorneal tear 
film for the treatment of keratoconjunctivitis sicca (Refojo, 1974). 
Bloomfield et al. (1977) found that sixty to ninety percent of the 
insert dissolved within five hours. The total dissolution time of.these 
devices ranges from eight to twelve hours (Gelatt et al., 1979). This 
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type of insert does not release a drug; therefore, it is not applicable· 
to the treatment of BIK. 
Maichuk (1975a) ·produced a soluble ophthalmic drug insert composed 
of poly (acrylamide), ethylacetate, and vinylpyrrolidone that dissolved 
in thirty minutes. Various ophthalmic drugs (such as neomycin, 
kanomycin, atrophine, pilocarpine, idoxuridine, and methasone mixed with 
the polymer) are released at the dissolution rate, prolonging the 
availability of active substances in conjunctiva! and corneal tissue for 
thirty-four to seventy-two hours. Clinical testing with more than 500 
patients showed good tolerance of the insert and therapeutic efficacy in 
various forms of glaucoma, keratitis, cornea ulceration, trachoma, 
conjunctivitis, adenovirus, and herpesvirus. This type of device is 
unable to maintain a therapeutic level of drug for the duration needed-
to treat BIK. 
Ocusert3 , an ocular insert that provides control of intraocular 
p_ressure for one week on a twenty-four hour basis, consists of 0.074 mm 
thick outer membranes of poly (ethylene-vinyl acetate) and a pilocarpine 
core. A titanium dioxide annular-ring surrounds the pilocarpine core to 
prevent drug escape from the edges. There are two systems current.ly in 
use. Pilo-20 contains 5 mg of pilocarpine and maintains a release rate 
of 20 ug/hr for seven days. Its exterior dimensions are 5.7 x 13.4 mm 
on its axis and 0.33 mm in thickness (Figure 2). Pilo-40 contains 11 mg 
of pilocarpine and maintains a release of 40 ug/hr for seven days. Its 
3 Alza Pharmaceuticals, Palo Alto, California. 
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Exterior of polymer-~~~~~~~~~~--
Dru<?-~-t--t-­
Ti tanium dioxide ring--"<~:-----~~~~----
FIGURE 2. Ocusert® exterior (Top-view). (Chien, 1982) 
exterior dimensions are 5.5 x 13 mm on its axis and 0.5 mm in thickness 
(Figure 2) (Chien, 1982). Figure 3 illustrates the release 
characteristics for the Pilo-20.' The average release rate for the first 
eight hours is 64 ug/hr. After this period, a 20 ug/hr release rate is 
maintained for seven days. At seven days the core is no longer 
saturated; consequently, first order release occurs (Cowsar, 1974; 
Richardson, 1975). 
Macoul and Pavan-Langston (1975) utilized a questionnaire format to 
examine the experiences of twenty-nine patients utilizing Ocusert®. The 
questionnaire was completed at specific times throughout a one yea.r 
period. Eighty-nine percent of the responses preferred the Ocusert® 
system to eyedrops. None of the responses indicated a problem with 
insertion, 0.3 percent of the responses expressed a frequent awareness 
of the insert in the eye, and 6.7 percent of the responses indicated 
that the device dislodged from the eye. 
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FIGURE 3. Pilo-20 release rate characteristics. (from Macoul and 
Pavan-Langston, 1975) 
Proposed treatment method 
·The controlled-release system is the only method of ocular drug 
delivery that is capable of maintaining a therapeutic leve1 in the eye 
for seven days. Controlled-release delivery.systems are classified by 
the release rate mechanism, and diffusion-controlled systems are the 
most prevalent. The two types of diffusion-controlled systems are 
reservoir and monolithic. A nonporous or microporous polymer film 
surrounds the drug in the reservoir system. Zero-order release occurs 
when the design maintains unit thermodynamic activity immediately inside 
the rate-limiting membrane (Hophenberg and Hsu, 1978). Reservoir 
systems are not biodegradable and leaks may develop. The drug is 
uniform.ly mixed throughout the solid nonbiodegradable polymer in the 
monolithic system. With excess dispersed drug, release is proportional 
18 
to the square root of drug loading·, and the rate slowly decreases in 
accordance with the square root of time rate law· ( Cowsar, 1974; Langer 
et al., 1980). 
An acceptable treatment drug must effectively eradicate BIK 
causative and contributory organisms. Two commonly utilized drugs are 
penicillin and streptomycin; however, in actual practice they are hot as 
effective as several other choices. Drugs that are effective against 
Moraxella bovis and Mycoplasma bovoculi are tetracycline, erythromycin, 
and tylosin-. Of these three, the minimum inhibitory concentration (0.63 
ug/ml), is lowest for tylosin. (R. F. Rosenbusch, personal 
communication.)4 Thus, treatment could be accomplished with a smaller 
amount of tylosin within the controlled-release system than if 
tetracycline or erythromycin were utilized. 
Tylosin (see Figure 4 for the structure), a macrolide antibiotic 
isolated from a strain of Streptomycetes fradiae in a soil sample from 
Thailand (McGuire et al., 1961; Hamill et al., 1961), is a weak base 
that forms soluble salts and ester compounds such as tylosin 
hydrochloride, tylosin tartrate, acetyltylosin, and propionyltylosin. 
The tylosin salts produced by the isolation and extraction process are 
pure enough to be utilized in that form (Korzybski et al. , 1967), and 
tylosin tartrate is commercially available for agricultural use (Burger, 
1970). Tylosin tartrate is soluble in water at concentrations greater 
than 300 mg/ml and is stable at room temperature in aqueous solutions 
4 Veterinary Medical Research Institute, Iowa State University, 
Ames, Iowa. 
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a 
FIGURE 4. Structure of tylosin. (from Windholz et al., 1976) 
(pH 4.0 - 9.0) for a least one month (Ose and Barnes, 1960). Trade 
names for the tylosin base are Tylan® and Tylocine® (Charles et al., 
1979) • 
The structure of the corneal membrane consists of an aqueous layer 
(stroma) covered by lipid layers (epithelium and endothelium). Drugs 
that are both hydrophobic and hydrophilic easily penetrate corneal 
tissue; however, pure polar or pure nonpolar drugs do not effectively 
penetrate the cornea (Chiou and Watanabe, 1982). Tylosin is soluble in 
lower alcohols, esters, ketones, chloronated hydrocarbons, benzene and 
ether; therefore, it is an amphipathic compound (Windholz et al., 1976). 
The antibiotic is essentially nontoxic and nonirritating to the eye and 
conjuctival sac (Ellis and Barnes, 1961; Johnston, 1982). 
An ocular controlled-release system of.biodegradable material would 
be particularly useful since subsequent system removal would not be 
required. 
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Biodegradable materials suitable for drug delivery systems are poly 
(lactic acid}, poly (glycolic acid), poly (£-caprolactone) and poly 
(amino acids) (Bruck, 1981; Langer and Peppas, 1981). 
Schindler et al. (1977) utilized in vitro methods to study the 
release of the steriods norgestrel, norethindrone, testosterone, 
progesterone, and ethynyl estradoil 1 from homo and copolymers of 
glycolide, dilactide, and £-caprolactone cylinders 1-2 cm in length with 
a 0.4-2.3 mm wall thickness. These configurations produced a release 
rate characterized by a rapid decline in rate during the first twenty 
days followed by a slow decline for the next 130 days. They found that 
copolymers of £-caprolactone and racemic dilactide were more permeable 
than poly (£-caprolactone) and are appropriate for devices with a 
lifespan of less than one year. Utilizing the same steriods, Pitt et 
al. (1979) showed that poly (lactic acid) films were 10 4 times less 
permeable than poly (£-caprolactone) films. The aqueous solubilities of 
the steroids at 37°c is, norgestrel 3.0 ug/ml, ,norethindrone 9.8 ug/ml, 
testosterone 30.6 ug/ml, progesterone 14.1 ug/ml and ethynyl estradiol 
12.1 ug/ml (Pitt et al., 1979). 
Schindler et al. (1977) found that it takes an average of eighty 
days for poly (dilactide) films implanted in rabbits to degrade to half 
of their original molecular weight. This degradation rate is 2.8 times 
greater than the degradation rate of poly (£-caprolactone) measured 
under the same conditions (Pitt et al., 1981). Copolymers of dilactide 
and £-caprolactone degrade more rapidly than either homopolymer. Figure 
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5 illustrates the fractional change in viscosity for the three materials 
versus time. 
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FIGURE 5. Fractional changes in the intrinsic viscosity of (a) poly , 
(e-caprolactone), (b) poly (dilactide), (c) poly 
(e-caprolactone-co-dilactide) with time. (from Pitt et al•,. 
1981) 
The release of sulfadiazine, an antimalarial drug, from a 1.5 mm 
diameter spherical matrix system of poly (lactic acid) implanted 
subdermally in rats decreased in accordance with the square root of time 
law (Wise et al., 1979). The aqueous solubility of sulfadiazine is 0.13 
mg/ml (Windholz et al., 1976). 
Poly (amino acids) are too weak for utilization as sutures and 
solubilize in a few days; however, the materials may be effective in 
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short duration, low strength drug release applications (Kronenthal, 
1975). 
These references illustrate that biodegradable polymers are capable 
of providing near zero-order release from reservoir devices and square 
root of time law release from matrix devices for relatively low water-
soluble drugs with molecular weights around 300. Therefore, it may be 
possible to release tylosin tartrate with its greater water solubility 
and higher molecular weight from similar devices. The literature search 
revealed no ocular applications of the biodegradable materials, and 
showed that the most common ophthalmic materials were silicon r.ubber, 
poly (methyl methacrylate) [poly (MMA)], and hydrogels (Reifojo, 19?4) .. 
Silicon rubber has been utilized extensively. for surgical . 
procedures within the globe of the ·eye. As a contact lens or ocular·, .,. 
insert, its high oxygen permeability permits the cornea t,0 obt'ain 
·;'.- ;:' ': 
required oxygen from the atmosphere; however, its hydrophobiC: nature , . 
causes eye irritation. Manufacturing difficulties are also a limitation· 
to the production of silicone rubber contact lenses (Refojo, i974). 
Poly (MMA) (Figure 6) is a high optical quality, light weigh:t,-
nonirritating material with excellent molding and machining ;o.;, •." 
''. '"'-
characteristics. Contact lenses of poly (MMA) are relatively · 
hydrophobic, absorbing 1. 5 percent water by weight (Refojo., 1974). The 
methyl methacrylate·monomer content should not exceed 0.~5 percent 
(Estevey and Ridley, 1966), since it is moderately toxic when absorbed· 
into the body; however, a 2-HEMA/MMA copolymer hydrogel stored in an 
. 
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FIGURE 6. Structure of 2-hydroxyethyl methacrylate (2-HEMA) and methyl 
methacrylate (MMA). (from Langer and Peppas, 1981) 
aqueous medium for a period of time is likely to consist only of polymer 
' network and the swelling medium (Refojo, 1969). 
Hydrogels are water-swollen, water-insoluble, polymeric materials 
with an equilibrium water content of up to ninety percent (Ratner and 
Hoffman, 1976; Pedley et al., 1980). Poly (2-hydroxyethyl methacrylate) 
[poly (2-HEMA)] is the most frequently utilized material due its 
stability under varying pH, temperature and toxicity conditions. It has 
an equilibrium water content of forty percent that can be reduced by 
copolymerization with methyl methacrylate [(MMA)] or increased by 
copolymerization with N-vinyl py'rrolidone [ (NVP)], methacrylic acid 
[(MA)]. or poly (vinyl pyrrolidone) [poly {VP)] (Pedley et al., 1980). 
Figure 7 illustrates equilibrium water content variation of MMA/2-HEMA 
copolymers. Hydrogel drug delivery systems are effective for. antibiotic 
release into areas with primary or secondary infection since they permit 
protracted drug release at optimum concentration to the immediate 
environment (Pedley et al.,· 1980). 
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FIGURE 7. Equilibrium water content of MMA/2-HEMA copolymers, (from 
Cowsar et al., 1976) 
Poly (2-HEMA) (Figure G) has an equilibrium water content of forty· 
percent (Pedley et al., 1980). It is extensively utilized by the soft-
contact lens industry due to its biocompatibility, and excellent 
machining and molding characteristics (Refojo, 1974). Poly (2-HEMA) 
disks produced no reaction when implanted within the corneal stroma for 
two months (Langer et al., 1981). 
Several reported drug release systems have poly (2-HEMA) or poly 
(2-HEMA)/poly (MMA) copolymers as the control membrane. Poly (2-HEMA) 
tubes {3 mm inside diameter, 5 mm outside diameter and 2.54 cm long) 
were filled with a cyclazocine polymer blend containing 140.G gm of 
cyclazocine (M.W. 271.39). Zero-order release of the highly water-
soluble narcotic antagonist into' an agitated, 37°C, phosphate buffer 
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solution of pH 7.4 at a rate of 1 mg/day for five months was achieved 
(Abrahams and Ronel, 1975). Cardinal et al. (1980) studied the release 
of a 100 mg progesterone (M.W. 314.45) silicone oil blend from poly 
(2-HEMA) tubes (2.85 cm long, 1.2 mm wall thickness) into agitated, 
23°C, deionized water. ·The release rate dropped from 0.15-0.04 mg/day 
for the first twenty days and remained zero-order at 0.04 mg/day until 
experiment termination thirty days later. Ebert et al. (1980) produced 
monolithic devices of poly (2-HEMA), prostaglandin E1 , and heparin that 
provided a release rate capable of reducing surface thrombosis for a 
period of seventy-two hours. The release characteristics followed the 
square root of time rate law. 
Various sized 50:50 MMA/2-HEMA copolymer rectangular slabs with a 
.sixty-two or eighty weight percent load of sodium fluoride were dip-
coated with a 70:30 MMA/2-HEMA copolymer to provide a coating with a 
thickness ranging from 0.11-0.28 mm. A synthetic-saliva, constant-
temperature flow system apparatus was utilized for the diffusion 
·experiment. Zero-order release rates of 0.02-1.0 mg/day for sixty days 
were obtained. The copolymer-sodium fluoride core provides a medium of 
fixed geometry and water content in which the fluoride salt dissolves 
before passing through the outer membrane. This maintains unit 
thermodynamic activity and prevents rapid release should the system fail 
(Cowsar et al., 1976). 
Olanoff and Anderson (1979) utilized 15 mm diameter trilaminar 
devices consisting of a tetracycline--63:37 MMA/2-HEMA matrix core 
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covered with 98:2 MMA/2-HEMA coatings of 0.053-0.14 mm thickness to 
release tetracycline (M.W. 444.43; water solubility 1.7 mg/ml). The 
zero-order release rate of tetracycline into Ringer's solution was found 
to be a function of general device geometry, coating membrane thickness, 
disk surface area, level of core reservoir drug .loading and membrane 
coating copolymer composition. Zero-order release rates.in the range of 
0.54-28.9 ug/day were reported. The outer coating was more hydrophobic 
than the inner core and controlled drug diffusion. The more hydrophilic 
core maintained the constant thermodynamic activity of the drug at the 
core-coating material junction as ·required for zero-order release. 
The desired ocular controlled-release system is required to 
maintain a minimum tylosin concentration of 0.63 ug/ml for seven days. 
The instantaneous volume of lachrymal fluid in the bovine may be 
approximated as 500 ul. (R. F. Rosenbusch, personal communication.)5 
Utilizing a catherization method of collecting lachrymal flui.d from 
cattle, Hoffman and Spadbrow (1978) obtained mean flow rates with a 
range of 0.18-1.86 ml/hr; Slatter and Edwards (1982) obtained mean flow 
rates of 1.96 ± 1.84 ml/hr (± s.d.). The ocular insert release rate 
requirements will vary due to different possible lachrymal fluid flow 
rates. However, the range of interest is known. 
The hydrogel reservoir and monolithic/reservoir systems described 
above have achieved zero-order release characteristics and are composed 
of acceptable ophthalmic materials. The wide range of zero-order 
5 Veterinary Medical Research Institute, Iowa State University, 
Ames, Iowa. 
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tetracycline (M.W. 444.43; water solubility 1.7 mg/ml) release 
(0.54-28.9 ug/day) obtained by Olanoff and Anderson (1979) indicates 
that reservoir and monolithic/reservoir systems with a 98:2 MMA/2-HEMA· 
control membrane may be utilized to provide zero-order release of 
tylosin tartrate (M.W. 1066.14; water solubility 300 mg/ml). Olanoff 
and Anderson (1979) and Olanoff et al. (1979) produced the 98:2 
MMA/2-HEMA copolymer by polymerizing a 90:10 MMA/2-HEMA molar feed ratio 
of monomers. The composition of the copolymer was determined by nuclear 
magnetic resonance analysis. This study duplicated the copolymerization 
procedures utilized by Olanoff and Anderson (1979); therefore, a similar 
copolymer product is expected. 
Quantitative analysis methods for tylosin tartrate 
The absorbancy (absorbancy=absorbance x 10000/concentration 
(ug/ml)) of a one percent solution of tylosin tartrate in a cell with a 
one centimeter.path is 255 at a wavelength of 290 nm. (B. Goodlow, 
personal communication.)6 Therefore, spectrophotometry may be used to 
determine tylosin tartrate concentration in an otherwise unvarying 
solvent. Hoffman and Spadbrow (1978) found that the protein 
concentration in lacrymal fluid varied inversely with the flow rate and 
had a range of 2.94-12.35 mg/ml. Thus, spectrophotometry is not an 
acceptable method of measuring tylosin tartrate concentration in 
lacrymal fluid. 
6 Sigma Chemical Company, Technical Service Representative, St. 
Louis, Missouri. 
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Thin layer chromatography (TLC) eliminates interference by other 
similarly acting agents since it is based on chemical and physical 
properties and not pharmacological properties; therefore, it is of 
possible interest. Debackere and Baeten (1971) utilized Silica Gel 254 
TLC plates? and the developing and visualization process shown in Figure 
8 to detect tylosin tartrate at concentrations of 2-4 ppm in water, 
blood plasma, urine, milk, tissue homogenates, and feed. The 
quantitative analysis of tylosin tartrate was performed by eluting ·the 
spots from the plate and conducting a spectrophotometric analysis of the 
eluted sample. This method of TLC analysis is time consuming, and 
technological advances since this study may permit a more sensitive, 
less time consuming analysis .. 
Commercially manufactured TLC plates have uniformly dispersed 
stationary phases of r.eproducible thickness. This development, and the 
simultaneous improvements in densitometer instrumentation permit 
quantitative analysis of samples directly on TLC plates. The relative 
standard deviation due to instrument variation is less than one percent, 
and quantitative determinations can achieve reproducibility of ± 2 
percent (Touchstone and Dobbins, 1978). A densitometer trace of zones 
with increasing sample weight, constant volume, and constant zone 
diameter results in a linear relationship between peak area and weight 
(Stahl and Jork, 1968). Table 3 summarizes the various peak area 
measurement techniques. The first four methods were available in 
7 Merck and Company Inc., Rahway, New Jersey. 
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Sample homogenization, 
. deproteinization and 
extraction 
i 
Alkaloid spotting 
and developing 
/"\ 
Samples from 
water, milk, blood plasma 
Samples from 
urine, feeds, tissues 
One-dimensional developing 
60:40 chloroform-acetone 
Two dimensional developing 
60:40 chloroform-acetone, 
85:15 ethyl acetate-methanol 
/ 
Identify tylosin 
with UV at 
254 nm 
Consecutive application of 
visualizing sprays, 
acid iodoplatinate, 
Dragendorff's reagent, 
saturated silver sulphate 
in 10% sulfuric acid 
a(Debackere and Laruelle, 1964) 
FIGURE 8. Thin layer chromatography developing and visualizing 
procedure for detecting tylosin tartrate. (Debackere and 
Baeten, 1971) 
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performing the work to be reported; selection of the "cut and weigh" 
method permitted good relative precision and provided a method of coping. 
with irregularly shaped peaks. Touchstone and Dobbins {1978) found that 
peak height to width at half-height ratios of 1-10, and Rf values in the 
range of o. 3-0. 7 improved the accuracy of the "cut and weigh" method. Rf 
is, defined as 
center-of-sample distance from zero reference 
developing-solvent-front distance from the zero reference 
where the preadsorbent layer-stationary phase interface is the zero 
reference. Within the 0.3-0.7 Rf range, the sample area per unit of 
solute is most uniform; therefore, the densitometric analysis is most 
accurate. 
·TABLE 3. Relative precision of peak-area measurement techniques. (fiom 
Snyder and Kirland, 1974) 
Method 
Planimeter 
Triangulation 
Cut and Weigh 
. Height x 1/2 width 
Bail and' disk integrator 
Electronic digital integrator 
Computer 
Relative precision 
1 s.d. (%) 
3 
3 
2 
2 
1 
0.5 
0.25 
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Early TLC work utilized a stationary phase that was more polar than 
the mobile phase (normal phase); however, a nonpolar, hydrocarbonaceous 
i 
stationary phase and relatively more polar mobile phase (reverse phase) 
is useful for the separation of nonpolar compounds such as hydrocarbons, 
lipids, fatty acids, carotenoids, steroids, triglycerides, vitamins, and 
cholesterol esters (Sherma, 1981). The reversed phase plate is 
therefore of interest to provide a separation of tylosin from the other 
components of lachrymal fluid. (H. M. Stahr, personal communication.) 8 
.The hydrophobic stationary phase of the reversed phase plate limits the 
choice of spotting solvent to those that will produce small initial 
zones; unfortunately, these solvents may not solubilize the sample. An 
inert preadsorbent layer comprising the first two or three centimeters 
of the TLC plate acts as. a blotter and reduces unfavorable spotting 
solvents to strong acids and bases (Sherma, 1982). Table 4 summarizes 
addit·ional advantages of preadsorbent TLC plates compared with 
conventional plates. The preadsorbent layer is of particular import.ance 
to this study because it permits direct spotting of aqueous tylosin-
saline solutions, eliminating the extraction process. 
The improved resolution and sensitivity of detection permit more 
precise direct quantitative analysis with a densitometer, and the 
improved reproducibility of Rf values reduces scanning time. 
8 Veterinary Diagnostic Laboratory, Iowa State University, Ames, 
Iowa. 
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TABLE 4. Advantages of preadsorbent TLC compared with conventional TLC. 
(from Sherma, 1982) 
Rapid application of high volumes and dilute solutions 
Automatic formation of uniform, narrow streaks at the layer 
interface 
Improved resolution 
Improved sensitivity of detection 
Improved reproducibility of Rf values 
Improved precision of quantitation by scanning 
Less required sample cleanup because of retention of salts and 
certain insoluble interfering organic compo.unds in the 
preadsorbent 
Analytes that may become irreversibly sorbed on active silica gel 
during drying of applied spots can be successfully chromatographed 
since substances do not contact the silica gel until they have 
passed through the preadsorbent, and then only in dissolved form 
Very dilute solutions can be applied by immersion of the 
preadsorbent in the sample solution 
The preadsorbent reversed phase TLC plate chosen for this 
application is the Whatman LKC 18 F9, The union of the preadsorbent layer 
and octadecy.lsilane reversed phase TLC has resulted in a ten to thirty 
percent increase of resolving power over normal phase conventional 
plates (Sherma, 1982). 
9 Whatman Chemical Separation Inc., Clifton New Sersey. 
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Whatman LKC 18 F TLC plates are coated with a silicon oil powder 
during the manufacturing process, and this powder produces a random 
pattern of brown and black spots when the TLC plate is visualized with 
sulfuric acid--methanol spray and heat. Full development of the TLC 
plates in methanol, before spotting, washes the silicon oil powder from 
the surface; consequently, a uniform, white-background is achieved on a 
visualized TLC plate. (H. M. Stahr, personal communication.) 10 
Whatman Chemical Sepa~ation Inc. (1981) recommends an 80:20 
methanol/water solution as a starting point for the selection of a 
developing solution. 
Charring, spraying a developed, preheated (110°C) silica gel TLC 
plate with concentrated sulfuric acid, is a common method of visualizing 
antibiotics. This process produces dark zones against a white 
background (Wagman and Weinstein, 1973). However, Whatman LKC 18 F TLC 
plates have octadecylsilane chemically bonded to the silica gel; 
consequently, charring techniques produce background discoloration 
(Sherma, 1981). Sherma (1981) recommends a uniform 90:10 
methanol/sulfuric acid spray followed by 110-170°C heat for two to five 
minutes as a visualization method. He found spraying preferable to 
dipping as the former produced a lighter background. 
10 Veterinary Diagnostic Laboratory, Iowa State University, Ames, 
Iowa. 
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PROCEDURES AND MATERIALS 
Production of 90:10 1111A/2-HEl1A Copolymer Films 
The following materials were added in the order listed to the one-
liter Erlenmeyer flask of the experimental apparatus shown in Figure 9: 
570.0 ml of ethanol, 380.0 ml of type-one waterl, 6.1 ml of 2-HE11A2 , 
46.6 ml of MMAa, 0.2507 gm of sodium persulfate 4 , and 0.1253 gm of 
potassium persulfates. 
The flask was sealed with a rubber stopper and the liquid contents 
were bubbled with nitrogen for thirty minutes. After thirty minutes, 
slight positive nitrogen pressure was maintained on the system for the 
ten day copolymer.ization reaction carried out at room temperature 
(21-23°C). On day ten, the white copolymer precipitate and solvent were 
added to a four-liter beaker containing three liters of type-one water. 
Suction filtration of the copolymer was completed with a Buchner funnel 
and 7 .0 cm, I-qualitative filter paper• .. After the initial filtration, 
1 American Society for Testing Materials definition; 0.1 mg/l 
maximum total matter, 0.06 micromho/cm maximum electrical conductivity 
at 25°C, 16.67 megaohm.cm minimum electrical resistivity at 25°C, 60 
minutes minimum color retention time of potassium permanganate, no 
detectable soluble silica. 
2 Polysciences Inc., Lot #2-2405, Ophthalmic Grade, Warrington, 
Pennsylvania. 
3 Adlrich Chemical Company Inc., Lot #041557, Milwaukee, Wisconsin. 
4 Aldrich Chemical Company Inc., Lot #060BHK, Milwaukee, Wisconsin. 
5 Fisher Scientific Company, Lot #714237, Fair Lawn, New Jersey. 
6 ward R. Balston Limited, London, England. 
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the copolymer in the funnel was washed four times with 25 ml amounts of 
type-one water before being placed into a 190 x 100 mm Pyrex glass 
container for drying. The storage container was covered with a filter 
paper1 top which prevented contaminants from entering during the five 
day drying period (drying temperature of 50°cB 25 in Hg vacuum 9 ). 
Copolymer films (90:10 MMA/2-HEMA) were produced by the following 
process. Two grams of 90:10 MMA/2-HEMA copolymer, 12.0 ml of acetone, 
and 8.0 ml of dimethylformamidelO were added to a 50 ml Erlenmeyer flask 
in the.order listed. The flask was covered with a weighted watch glass 
(75 gm) and placed onto a preheated magnetic stirrer. Mixing and 
heating rates were adjusted to produce 200 rpm and 33-35°C values, 
respectively. After ten hours of mixing and heating, the solution was 
dispersed in approximately equal amounts onto three, siliconizedll, 75 x 
50 mm plain-glass microscope slides. The films were produced by slowly 
pouring the solution from the Erlenmeyer flask in the pattern shown in 
Figure 10. Solution did not cover the entire slide; therefore, it could 
seek its own level. The poured films were immediately covered with a 
petri dish top, and were kept at room temperature (21-23°C) for the 
1 Whatman Limited, Type !-qualitative, London, England. 
B Chicago Apparatus, Model 524 A, Chicago, Illinois. 
9 The Welch Scientific Company, Duo Seal® Vacuum Pump, Model 1402, 
Skokie, Illinois. 
10 J. T. Baker Chemical Company, Lot #35107, Phillipsburg, New 
Jersey. 
11 PCR Research Chemicals, Inc. Prosil-28, Gainesville, Florida. 
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END /------,~/ 
FIGURE 10. Pouring pattern for 90:10 MMA/2-HEMA films 
evaporation process. Forty-eight hours after pouring, the cured films 
were separated from their glass slide by immersion into type-one water. 
The films floated free of the glass slide within five minutes. The 
separated films were soaked for ninety-six hours in a 600 ml glass 
beaker containing that same amount of type-one water. At twenty-four 
hour intervals, the type-one water was changed. 
After the four-day soaking period, the films were removed from the: 
beaker and immediately cut with a corkborer into 17.9 mm diameter disks. 
The disks were stored at room temperature {21-23°C) in a glass petri 
dish. After twenty-four hours, the disks were dry. The thickness of 
the dry disks was directly measured with a micrometer12 and scanning 
electron microscopy13 was utilized to obtain microstructural 
12 L. S. Starrett Company, Model EDP 50940, Athol, Massachusetts. 
13 Japanese Electron Optics, Limited, Model U3, Tokoyo, Japan •. 
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information. The disks were stored at room temperature in 15 x 10 cm 
polyethylene storage bags until needed. 
Fabrication of Poly (Lactic Acid)-Tylosin Tartrate Matrix by the 
Cold Process 
Rhine et al. (1980) produced a poly (ethylene/vinyl acetate)-
protein matrix with uniform particle dispersion. Their fabrication 
procedures were adapted to produce a poly (lactic acid)-tylosin tartrate 
matrix. 
One hundred milligrams of poly (lactic acid)14, 100 mg of tylosin 
tartratels and 5.0 ml of methylene chloride16 were added in the order 
listed to a 25 ml Erlenmeyer flask. The flask was covered·with a 
weighted watch glass (75 gm) and placed onto a magnetic stirrer. Mixing 
for five minutes at 100 rpm produced a solution. A 100 x 15 mm dispos-
able petri dish was packed with granulated dry ice, and a siliconized, 
75 x 50 mm plain-glass microscope slide was precooled for five minutes 
by placing it on top of the sealed petri dish. During precooling, the 
slide was covered with a second slide to prevent frost formation. 
When the five minute mixing and precooling period elapsed, 4.4 ml 
of solution were pipetted onto the precooled, siliconized, glass slide 
by the pattern shown in Figure 11. The slide remained on the petri dish 
14 Polysciences Inc., Lot #23062, Warrington, Pennsylvania. 
15 Sigma Chemical Company, Lot #89C-0315, St. Louis, Missouri. 
16 Fisher Scientific Company, Lot #721513, Fair Lawn, New.Jersey. 
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FIGURE 11. Pouring pattern for poly (lactic acid)-tylosin tartrate. 
matrix 
for ten minutes; the first three minutes it remained uncovered, and the 
last seven minutes it was covered with a disposable petri dish top. 
After ten minutes, the slide was transferred to a freezer (-20°C) for 
forty-eight hours. Upon removal from the freezer, forceps were utilized 
to pull the poly (lactic acid)-tylosin tartrate matrix from the 
siliconized glass slide. The matrix was transferred to a 160 x 255 mm 
glass desiccator and kept at room temperature (21-23°C). under a 1 mm Hg 
water-flow vacuum for forty-eight hours. 
After forty-eight hours in the desiccator, the matrix was removed 
and immediately cut with a corkborer into eight 16.2 mm diameter-disks. 
Each disk was weighed17, and its thickness was determined by placing a 
disk between two 3 x 1 inch plain-glass microscope slides of known 
thickness and measuring the change of thickness with a micrometer. 
17 Mettler Instrumente AG, Model H31AR, Zurich, Switzerland. 
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Microstructural information was obtained by scanning electron 
microscopy. The disks were kept at room temperature in 15 x 10 cm 
polyethylene storage bags until needed. 
Fabrication of Poly (Lactic Acid)-Tylosin Tartrate Matrix by the Roam 
Temperature Process 
I ' 
One hundred milligrams of,tylosin tartrate, 0.1 gm of poly (lactic 
acid) and 9 ml of methylene chloride were added in the order listed to a 
25 ml Erlenmeyer flask. The flask was covered with a weighted watch 
glass (75 gm) and placed onto a magnetic stirrer. A solution was 
produced after mixing at 100 rpm for five minutes. 
When the five minute mixing period elapsed, 4.4 ml of the solution 
were pipetted onto a siliconized, 75 x 50 mm plain-glass microscope 
slide by the pattern shown in Figure 11. The slide was covered with a 
petri dish top for the twenty minute room temperature (21°C) evaporation 
process. The dry film was pulled from the.slide with forceps and was 
kept at room temperature in 15 x 10 cm polyethylene storage bags until 
needed. 
Fabrication of Controlled-Release Systems 
Three types of trilaminar systems were produced in quintuplicate. 
Table 5 indicates the composition of e~ch layer. The following 
procedure was utilized to join the outer layers together. One gram of 
90:10 MMA/2-HEMA copolymer, 6.0 ml of acetone, and 4.0 ml of 
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TABLE 5. Composition of trilaminar controlled-release systems 
Controlled-release 
system sample 
number 
32A 
328 
32C 
320 
32E 
33A 
338 
33C 
330· 
33E 
34A 
348 
·34c 
340 
34E 
Composition of 
inner layer 
16.2 mm diameter 
poly (lactic acid)-
tylosin tartratea 
matrix containing 
approximately 4.84 mg 
of tylosin tartratea 
Tylosin tartratea 
(5 mg loading) 
Tylosin tartratea 
(50 mg loading) 
Composition of 
outer layer 
17.9 mm diameter 
disk of 90:10 
MMA/2-HEMA 
17.9 mm diameter 
disk of 90: 10 
MMA/2-HEMA 
17.9 mm diameter 
disk of 90:10 
MMA/2-HEMA 
aSigma Chemical Company, Lot #89C-0315, St. Louis, Missouri. 
dimethylformamide were added in the order listed to a 50 m.l Erlenmeyer 
flask. The flask was covered with a weighted watch glass (75 gm) and 
placed onto a preheated magnetic stirrer. Mixing and heating rates were 
adjusted to produce 200 rpm and 33-35°C values, respectively. A cloudy 
solution formed in six hours. 
Figure 12 illustrates the assembly process. The·· bottom 90: 10 
MMA/2-HEMA disk was placed glass side down on a 75 x 50 mm plain-glass 
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FIGURE 12. Controlled-release system assembly diagram 
microscope slide. Tylosin tartrate was weighed directly onto the 90:10 
MMA/2-HEMA disk for controlled-release system samples 33A-E and 34A-E. 
By comparison, a 16.2 mm diameter disk of the poly (lactic acid)-
tylosin tartrate matrix (from the cold process) was placed on top of the 
90:10 MMA/2-HEMA disk for controlled-release system samples 32A-E. The 
90:10 MMA/2-HEMA solution produced above was dispersed along the outer 
perimeter of the 90:10 MMA/2-HEMA disk using a disposable lee syringe 
and 20G-l needle. A second 90:10 MMA/2-HEMA disk was applied glass side 
up, and a weighted 7S x SO mm plain-glass microscope slide (SS gm) 
covered the trilaminar system. Solvent evaporation at room temperature 
'· 
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(21-23°c) was completed in twenty-four hours. The edges of the 
completed controlled-release systems were examined for perforations at 
40X with a stereomicroscopelB, and completed disks were stored in glass 
petri .dishes at room temperature until utilized in the tylosin t.artrate 
release-experiment forty-eight hours later. 
Tylosin Tartrate Release-Experiment 
Each of the fifteen controlled-release systems was placed into a 20 
ml scintillation vial containing 2.0 ml of mammalian Ringer's 
solutionl9. The lids were lined with aluminum foil to prevent 
contamination of the samples from the glue used on the conventional cap 
liners, and the tightly sealed vials were placed into a shaking water 
bath2D operating at 60 rpm and 37°C. At the time intervals shown in 
Table 6, the 2.0 ml of mammalian Ringer's solution was removed from each 
vial using a 3 ml disposable syringe and 22G-l needle, and placed into a 
one-dram glass vial. A fresh 2.0 ml amount of mammalian Ringer's 
solution was added to each 20 ml scintillation vial by directing the 
flow into the bottom corner of the vial away from the insert. Each 20 
ml scintillation vial had a separate syringe for collection; however, a 
single syringe was utilized for addition of mammalian Ringer's solution. 
18 Nikon, Model 90783, Tokoyo, Japan. 
' 19 8.60 gm sodium chloride, 0.30 gm potassium chloride, 0.33 gm 
calcium chloride, combined in one-liter volumetric flask and filled with 
type-one water. 
2 ·° Fisher Scientific Company, Model 127, Pittsburgh, Pennsylvani'a'. 
. ·-. 
' '' , . 
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TABLE 6. Collection times for the tylosin tartrate release-experiment 
Sample number Time of collection Sample.number Time of collection 
from beginning of from beginning of 
experiment (hrs) experiment (hrs) 
1 4 11 60 
2 8 12 72 
3 12 13 76 
4 24 14 80 
5 28 15 84 
6 32 16 96 
7 36 17 100 
8 48 18 104 
9 52 19 108 
10 56 20 120 
The one-dram glass vials containing the collected samples were, placed 
into ari oven21 at 50°C and the liquid was totally evaporated. 
TLC Spotting, Developing, Visualizing, and Quantitative Procedures 
Whatman LKC 18 F, 20 x 20 cm, TLC plates22 were fully developed in a 
standard developing chamber23 containing methanol24. The developed 
21 GCA/Precision Scientific, Model 28, Chicago, Illinois. 
22 Whatman Chemical Separation Inc., Lot #002513, 002360, 002061, 
002280, Clifton, New Jersey. 
23 Whatman Chemical Separation Inc., Type CDC-12, Clifton, New 
Jersey. 
24 Fisher Scientific Company, Lot #734176, Fair Lawn, New Jersey. 
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plates were air-dried at room temperature for a period of at least four 
days. 
Ten microliter aqueous or saline solutions of tylosin tartrate were 
applied to the TLC plate with a Drummond 0-10 ul micropipette. Spotting 
was accomplished by depressing the plunger until an approximately 3 ul 
drop formed at the end of the glass dispenser tube. By touching the 
edge of the drop to the preadsorbent layer of the TLC plate, the drop 
was transferred to the plate. 
Room temperature air which was passed through a drying tube of 
Drierite® was subsequently blown across the TLC plate's surface to 
facilitate the evaporation process. 
When the spots were completely dried, each TLC plate was 
individually developed a distance of 8 cm in a standard developing 
chamber containing an eighty-five percent methanol and fifteen percent 
type-one water solution. Fresh solution was produced in 100 ml amounts 
and was utilized for each developing session. The chamber was 
equilibrated for one hour before developing TLC plates, and one side of 
the chamber was lined with filter paper25 to maintain chamber 
equilibrium. TLC plates were developed with the gel side facing the 
liner. Developed plates were air-dried at room temperature before 
beginning the visualization procedure. 
25 Whatman Chemical Separation Inc., Type 3MM-0,3 millimeter 
thickness, Clifton, New Jersey. 
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Visualization of the developed plate was accomplished by spraying26 
ten percent (by volume) sulfuric acid27 in methanol2 8 at a rate of 15 
ml/min for fifteen seconds, and placing the sprayed plate into a 100°C 
oven for ten minutes. After ten minutes of heating, the plate was kept 
at room temperature for fifteen minutes as fading of the tylosin 
tartrate sample occurred. After the initial fading, the tylosin 
tartrate samples maintained their intensity for several hours. 
Quantitative analysis was conducted during the 15-120 minute period 
following heating. 
A Kontes fiber optic scanner, model 8002 9 , was utilized to directly 
measure tylosin tartrate dark-spot intensity by cross scanning the TLC 
plate (perpendicular to the development direction). The output signal 
of the densitometer was transmitted to a linear plotter3° which produced 
a trace of peaks for subsequent evaluation of areas. The lower limit of 
a peak area was determined by connecting the baseline on either side of 
the peak with a straight line. Each TLC plate was analyzed twice; 
consequently, there were two peaks for each tylosin tartrate spot. The 
26 Kontes, Model K-422550, Vineland, New Jersey. 
27 Fisher Scientific Company, Lot #732068, Fair Lawn, New Jersey. 
28 Fisher Scientific Company, Lot #734176, Fair Lawn, New Jersey. 
2 ~ Kontes Scientific Instrument Group, Vineland, New Jersey. scan 
rate 2cm/min; du~l-~eam reflectance mode; phosphor coated disk #9660750 
(red filter), emission peak 615nm, bandwidth lOnm; attenuator adjusted 
to produce peak height to half-height width ratios of one to ten. 
30 Linear Instruments Corporation, Model 255/MM, Irvine, California. 
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peaks were cut-out and weighed. The arithmetic mean of the two weights 
was utilized in the computer analysis. 
Upon complet·ion of the densitometric analysis, Rf was determined. · 
Evaluation of TLC Quantitative Analysis of Tylosin Tartrate 
A• melting point determination for tylosin tartrate was conducted. 
Tylosin tartrate/type one water standards were produced by the followin9 
procedure. One hundred milligrams of tylosin tartrate and 10 ml of 
type-one water were added to a 15 ml ground glass test tube. The 
contents were initially mixed for three minutes with the Vortex-Genie 
Mixer3 1 (setting 5) to_ form a solution and were then placed into a dry, 
shaking water bath unit (setting B) for three hours to ensure uniform 
dispersion. Subsequently, a 1:100 dilution was performed, and this 
solutio'n was mixed in ·the same manner. The solution concentration was 
verified by a UV spectrophotometric analysis32. This analysis was 
conducted by measuring the absorbance (at 290 nm) of the tylosin 
tartrate type-one aqueous solution against a reference of pure type-one 
water. 
The original solution and the 1: 100 dilution wer·e utilized to 
.Prepare the tylosin tartrate standards.listed in Table 7. All dilutions 
were subjected to the mixing procedure outlined above, before subsequent 
dilutions were conducted. 
31 Scientific Industries Inc., Bohemia, New York. 
32 Varian/Instrument Division, Model 219, Palo Alto, California. 
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TABLE 7. Tylosin .tartrate standard concentrations (ug per 10 ui. of 
solution). 
0.10 
0.20 
0.30 
0.40 
0. so 
O.GO 
0.70 
0.80 
0.90 
1.0 
2.0 
3.0 
4.0 
5.0 
G.O 
7.0 
8.0 
9.0 
10.0 
Two separate experimental procedures were conducted. Seven, 10 ul-
amounts of a single standard were applied to a TLC plate at 2.0 cm 
intervals. This was repeated for each standard listed in Table 7. The 
method utilized to obtain the average weight of peak from a tylosin 
tartrate standard applied to a TLC plate may be found in the section 
entitled, TLC Spotting, Developing, Visualizing, and Quantitative 
Procedures. The average weight of peak for each of the seven standards· 
on a TLC plate was analyzed with a computer statistical analysis program 
(SPSS Inc., 1983). Maximum, minimum, mean, standard deviation, range 
and scattergram data were calculated. 
Standards were separated into three groups, 0.10-0.70, 0.80-5.0, 
and 4.0-10.0 for the second experiment. Ten microliters from each of 
the seven standards in a group was spotted onto a TLC plate at 2 cm 
intervals. Five TLC plates of each group were produced. The method 
utilized to obtain the average weight of peak from a tylosin tartrate 
standard applied to a TLC plate may be found in the section entitled, 
TLC Spotting, Developing, Visualizing, and Quantitative Procedures. The 
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average weight of peak for each of the seven standards on a TLC plate 
was analyzed with a computer statistical analysis program (SPSS Inc., 
1983). The coefficient of determination (r2), standard error, 
·regression line equation, and scatterplot data were calculated. 
Determination of the Tylosin Tartrate Concentration in the Release-
Experiment Samples 
The release-experiment samples were dried and sealed in one-dram 
glass vials with teflon screw caps at the beginning of this procedure. 
An Eppendorf pipette was utilized to add type-one water in 100 ul 
amounts until a solution was formed. Ten microliters from each sample 
were spotted onto a TLC plate at 1 cm intervals; thus, nineteen samples 
were on a single TLC plate. The spotting, developing, and visualizing 
process are outlined in the section entitled, TLC Spotting, Developing, 
Visualizing, and Quantitative Procedures. The sample spots of tylosin 
tartrate were visually compared with a TLC plate of tylosin tartrate 
standards to determine the need for subsequent dilutions. The dilution 
process was repeated until a tylosin tartrate concentration below 5.0 
ug/10 ul was obtained for each release-experiment sample. This dilution 
process utilized 100 ul, 500 ul, and 1000 ul Eppendorf pipettes. 
Quantitative analysis of the samples was conducted by applying a 10 
ul amount of five samples and five standards to a TLC plate at 1.5 cm 
intervals. Tylosin tartrate standards were selected to correspond with 
the visually determined sample concentration. The method utilized to 
obtain average weight of peak from the tylosin tartrate spots on a· TLC 
I 
I 
I 
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plate may be found in the section entitled, TLC Spotting, Developing,' 
Visualizing, and Quantitative Procedures. The average weight of peak 
for each of the five standards on a TLC plate was analyzed with a 
computer statistical analysis program (SPSS Inc., 1983). The 
coefficient of determination (r2), standard error, regression line 
equation, and scatterplot data were calculated. The average weight of 
peak for each of the five release-experiment samples was substituted 
into the regression line equation to calculate tylosin tartrate 
concentration. 
The above procedure utilized known concentrations of tylosin 
tartrate in a type-one aqueous solution to calculate the regression line 
equation. However, the average weight of peak substituted into the 
regression line equation to determine the amount of tylosin tartrate 
released was based on saline solutions of varyi~g concentration. The 
following procedures were utilized to determine the effect of saline 
concentration on the TLC quantitative analysis method. Tylosi~ tartrate· 
concentrations of 1.0, 2.0, 3.0, 4.0, and 5.0 ug/10 ul were produced 
utilizing type-one water and mammalian Ringer's solutions. Ten 
microliters from each of the ten solutions were applied to a Whatman 
LKC 18F TLC plate at 1.5 cm intervals, and the TLC plate was developed 
and visualized by the method previously described. A densitometer 
analysis was conducted to determine pattern intensity variation due to 
differences in saline concentration of the application solvent. 
. . 
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The variability of Rt and of spot diffusion due to different salt 
concentrations in the application solvents was examined by applying 10 
ul samples with varying saline concentrations, but identical tylosin 
tartrate amounts, to a Whatman LKC 18 F TLC plate. The saline 
concentrations were produced by the following procedure. Two milliliter 
mammalian Ringer's solutions (with the tylosin tartrate concentrations 
shown in Table 8) were placed into one-dram vials and totally evaporated 
at 50°C. The salts and tylosin tartrate were resolubilized by adding 
type-one water in the amounts shown in Table 8. Ten microliters of the 
three saline concentrations and a type-one water solution containing the 
same concentration of tylosin were applied in duplicate to a Whatman 
LKC 18 F TLC plate at 1.5 cm intervals, and the TLC plate was developed, 
visualized, and analyzed by the method previously described. 
The average weight of peak for each of the eight samples on a TLC 
plate was analyzed using a computer statistical analysis program (SPSS 
Inc., 1983). Maximum, minimum, mean, standard deviation, range and 
scattergram values were calculated. 
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TABLE 8. Preparation of application solvents with various salt 
concentrations 
Vial Tylosin tartrate Amount of type-one Amount of tylosin 
number in mammalian water added to dry ta:rtrate on a TLC 
Ringer's solution vial plate 
(ug/ml) (ul) (ug) 
1 10 100 2, 
2 30 300 2:·' 
3 50 500 2 
4 15 100 3 
5 45 300 3 
6 75 500 3 
7 20 100 4 
8 60 300 4 
9 100 500 ·4 
" ' ' ' ' 
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RESULTS 
Before thin layer chromatography could be utilized to detect the 
amount of tylosin tartrate in controlled-release experiment samples, the 
suitability and reliability of the process had to be established. 
Therefore, the first topics to be discussed are the TLC process and the· 
justification for the utilization of particular solutions and 
operational parameters. Next, the spot patterns of tylosin tartrate 
aqueous and saline solutions are compared and contrasted by examining 
spot shape, spot size, and Rf. 
This report utilized direct densitometric scanning of the TLC plate 
to quantify the amount of tylosin tartrate in a controlled-release 
experiment sample. In order to conduct such a procedure, the 
variability and linearity of the peak weight to tylosin tartrate 
relationship for aqueous solutions and the variability for saline 
solutions must be known. The results of the three experiments utilized 
to determine these values are discussed. 
The second area of emphasis in this report is the production of a 
controlled-release system that may be utilized for the treatment of BIK. 
Three types of devices were studied in quintuplicate. The discussion 
begins with the production of the control membrane and inner drug layer, 
and details scanning electron microscopy results of microstructural 
properties. Next, the controlled-release system assembly procedure is 
reviewed, and results of a pre-experiment examination of the systems 
with a stereomicroscope are given. 
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Finally, the details of the controlled-release experiment are 
reviewed, and the tylosin tartrate summary release profiles are 
presented in graphic and tabular form (complete data utilized to produce 
the profiles are located in the Appendices). The release profiles are . 
evaluated in relation to the appropriate lachrymal flow rate and the 
results of a post-experiment stereomicroscopic examination. 
TLC Spotting, Developing, Visualizing, and Quantitative Analysis Process 
for Tylosin Tartrate 
Full development (based on methanol) of 20 x 20 cm Whatman LKC 18 F 
TLC plates took approximately one hour, and provided a uniform, white-
background upon visualization. 
Ten microliter amounts of application solution were utilized for 
all cases. The 10 ul solution was applied in approximately 3 ul amounts 
because the drop remained at the end of the micropipette glass dispenser 
and could be transferred completely to the TLC plate. Larger drops 
tended to form along the side of the micropipette glass dispenser and 
would not transfer completely to the TLC plate. The room temperature 
air flow permitted the 10 ul amount to be applied in approximately three 
minutes. 
Developing solution of eighty-five percent methanol, fifteen 
percent type-one water produced Rf values in the 0.3-0.7 range. The~ 
results will be discussed in a subsequent section. 
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The ten percent (by volume) sulfuric acid in methanol visualization 
spray produced a white background and a brown tylosin tartrate pattern. 
Increased spraying or heating periods caused the background to darken. 
Conversely, the lower concentrations of tylosin tartrate were not 
visible with shorter spraying .and heating periods. 
The densitometer was operated in the dual-beam, reflectance mode. 
Figure 13 shows densitometer traces of the same three samples on a 
,Whatman LKC 18F TLC plate for the transmission, reflectance, and 
reflectance/transmission modes. The transmission mode consistently 
produced a more erratic baseline than the other two modes. The 
reflectance and reflectance/transmission modes both produced smooth 
baselines; however, the reflectance mode provided additional damping of 
inflection points on the peaks. Therefore, the dual-beam r~flectance 
mode was selected for densitometric analysis. 
The densitometer attenuator-control and the plotter input-control 
were adjusted to provide a smooth baseline and to be within a ratio of 
peak height to width at half-height of one to ten. Figures 14 - l& 
illustrate the peak traces for 0.2-0.8 ug, l.0-4.0 ug, and 5.0-10.0 ug 
of tylosin tartrate applied as a type-one aqueous solution. The peaks 
are uniformly shaped and the baselines are smooth. 
On some TLC plates, the visualized pattern for tylosin tartrate 
amounts near 0.2 ug lacked intensity. Thus, it was not always possible 
to maintain a smooth baseline and the desired ratio. In these cases, 
the smooth baseline was compromised somewhat in order to obtain a trace 
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(a) 
(b) 
(c) 
FIGURE. 13. Densitometer trace characteristics of {a) transmiss:lon mode, 
{b) transmission/reflectance mode, {c) reflectance mode 
0.2 ug 0.4 ug 0.6 ug 0.8 ug 
FIGURE 14. Densitometer trace for 0.2-0.8 ug of tylosin tartrate 
applied as a type-one aqueous solution. Densitometer 
attenuator-control 8, plotter input-control lOOmV 
1.0 ug 2.0 ug 3.0 ug 4.0 ug 
FIGURE 15. Densitometer trace for 1.0-4.0 ug of tylosin tartrate 
applied as a type-one aqueous solution. Densitometer 
attenuator-control 8, plotter input-control lOOmV 
5.0 ug 6.0 ug 7.0 ug 8.0 ug 9.0 ug 
FIGURE 16. Densitometer trace for 5.0-10.0 ug of tylosin tartrate 
applied as a type-one aqueous solution. Densitometer 
attenuator-control 16, plotter input-control lOOmV. 
Baseline distances reduced to accommodate peaks. 
10.0 ug 
GO 
near the desired peak height to width at half-height ratio. Figure 17 
shows a densitometer trace for this type of sample. The peaks have 
irregular shapes, and baseline fluctuations introduce uncertainty in the 
selection of the peak lower limit. Figure 18 illustrates the baseline 
location for these types of samples. The location results in 
approximately equal areas of fiuctuation above and below the baseline.· 
Fluctuations resulting from visible imperfections on the plate were 
discounted from this process. 
Densitometer scan-speed and plotter paper-speed were adjusted to 
conserve paper, yet produce a stable baseline recording between peaks. 
The peak width was also affected by these settings. 
Densitometric analysis of all plates was performed in duplicate to 
reduce errors from densitometer variation, chart paper differences, and 
the "cut and weigh" process. 
Tylosin Tartrate Type-One Aqueous Solution TLC Pattern 
Tylosin tartrate in a type-one aqueous solution on Whatman LKC18F 
TLC plates produced the pattern (brown) shown in Figure 19. A 0.1 ug 
quantity of tylosin tartrate was visible one of the twelve times that it 
was applied to six different TLC plates; however, 0.2-10.0 ug quantities 
were always visible. 
Figure 19 illustrates that each amount of tylosin tartrate in the 
range of 0.2-0.7 ug was visualized as a dark spot and a less intense 
band at greater Rf; 0.8-10.0 ug amounts were visualized in order of 
0.1 ug 0.2 q 0.3 ug 
FIGURE 17. Densitometer trace of tylosin tartrate in type-one aqueous 
solution for visualized patterns of low intensity. 
Densitometer attenuator-control 32, plotter input-control 
lOmV 
0.1 ug 0.2 ug 0.3 ug 
FIGURE 18. Baseline location for visualized patterns of low intensity. 
Densitometer attenuator-control 32, plotter input-control 
lOmV 
"' N 
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.2us .4us .&us .Sus 2us 4us &us Sus 10 us 
FIGURE 19. Tylosin tartrate pattern on a Whatman LKC 18 F TLC plate, 
applied as a type-one aqueous solution. 
increasing Rf, as a dark spot, a light, diffuse spot, and a band of 
medium intensity. Tailing of the dark spot occurs at 5.0-10.0 ug 
quantities of tylosin tartrate. The formation of a comet-like trail 
(tailing) will occur with any sample if sufficient material is applied 
to the TLC plate. 
Tylosin Tartrate Saline Solution TLC Pattern 
The saline concentration of the application solution influences 
spot diameter. Figure 20 is a photograph of a Whatman LKC 18 F TLC plate 
with 1.0-5.0 ug tylosin tartrate samples applied as 10 ul amounts of 
type-one aqueous solutions (left) and 10 ul amounts of mammalian 
Ri nger's solutions (right). The tylosin tartrate samples applied with 
the mammalian Ringer's solution produce diffuse, (brown) spot-patterns. 
The distance between the dark spot and light , diffuse spot and the 
light, diffuse spot and band of medium intensity are reduced for the 
mammalian Ringer's solution samples. 
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lug 2ug 3uc 4us Sus lus 2us 3us 4us Sus 
FIGURE 20. Variation of tylosin tartrate pattern with application 
solution. Type-one aqueous solution (left) and mammalian 
Ringer's solution (right) 
Tylosin Tartrate Type-One Aqueous Solution Rf 
Table 9 contains the Rf values for seven identical amounts of 
tylosin tartrate in a type-one aqueous solution, applied to a Whatman 
LKC 18 F TLC plate. Rf values of the tylosin tartrate groups on Whatman 
LKC 18 F TLC plates are listed in Table 10. The data indicate that the ~ 
values are quite reproducible. This reproducibility expedites the 
densitometric scanning process since it permits an entire plate to be 
cross-scanned without intermediate alignment. 
In all cases, the dark spot Rt's are within the 0.~-0.7 range 
suggested by Touchstone and Dobbins (1978). 
Tylosin Tartate Saline Solution Rf 
The variation of Rf due to different application solution saline 
concentrations was examined by applying various saline concentrations 
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TABLE·9. Rf values of seven identical amounts of tylosin tartrate on a 
Whatman LKC 18 F TLC plate, applied as a type-one aqueous 
solution 
Amount of 
TLC plate tylosin tartrate Dark spot Diffuse spot Band 
(ug) (Rf) (Rf) (Rf) 
1 0.2 0. 57 0.86 
2 0.3 0.56 0.66 
3 0.4 0.54 0.69 
~ 
4 0.5 0.57 0.93 
5 0.6 0.57 0.90 
6 0.7 0.56 0.63 
7 0.6 0.57 0. 71 0.86 
6 . 0. 9 0.57 0.71 0.86 
9 LO 0.57 0.73 0.86 
10 2.0 0.56 0.72 0.84 
11 3.0 o. 57 0.71 0.85 
12 4.0 o.58 0.69 0.85 
13 5.0 0.57 0.71 0.86 
14 6.0 0.58 0.72 0.85 
15 7.0 0.58 0.73 0.87 
16 8.0 0.58 0.72 0.87 
17 9.0 0.57 o. 71 0.88 
18 10.0 0.57 0.70 0.85 
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TABLE 10. ~ values of tylosin tartrate groups on Whatman LKC 18 F TLC 
plates, applied as a type-one aqueous solution 
Range of 
TLC plate tylosin tartrate Dark spot Diffuse spot Band 
(ug) (Rf) (Rf) (Rf) 
1 0.1-0.7 0.56 0.79 
2 0.1-0.7 0.59 0.88 
3 0.1-0.7 0.58 0.87 
4 0.1-0.7 0. 56 0.88 
5 0.1-0.7 0. 57 0.86 
6 0.8-5.0 0.57 0.72 0.88 
7 0.8-5.0 0.54 0.70 0.88 
8 0.8-5.0 0.55 0.72 0.87 
9 0.8-5.0 0.54 0.72 0.86 
10 0.8-5.0 0.56 0.71 0.87 
11 4.0-10.0 0.56 0.72 0.85 
12 4.0-10.0 0.57 0. 71 0.87 
13 4.0-10.0 0.57 0. 71 0.86 
14 4.0-10.0 0.56 0.72 0.87 
15 4.0-10.0 o. 56 0.72 0.87 
67 
with an identical tylosin tartrate amount to a Whatman LKC 18 F TLC plate. 
The Rf values obtained from this procedure are listed in Table 11. 
TABLE 11. Rf variation due to saline concentration differences of the 
application solution 
Amount of type-
TLC plate Amount of one water added Dark spot Diffuse Band 
tylosin to the salts of (Rf) spot (Rf) 
tartrate 2 ml of Ringer's (Rf) 
(ug) solution 
(ul) 
l 2.0 100% type-one 0.56 0.70 0.91 
water 
l 2.0 100.0 0.55 0.66 0.85 
1 2.0 300.0 0.69 0.83 0.94 
1 2.0 500.0 0.73 0.85 0.94 
2 3.0 100% type-one 0. 59 0.70 0.89 
water 
2 3.0 100.0 0.61 0.72 0.87 
2 3.0 300.0 0.70 0.83 0.95 
2 3.0 500.0 0.74 0.87 0.98 
3 4.0 100% type-one 0.56 0.70 0.88 
water 
3 4.0 100.0 0.54 0.66 0.78 
3 4.0 300.0 0.64 0.78 0.90 
3 4.0 500.0 0.68 0.80 0.94 
There are no significant differences in Rf between the one hundred 
percent type-one water and 100.0 ul saline solutions. However, the Rf's 
of the 300.0 ul and 500.0 ul saline solutions are consistantly greater 
than those of the corresponding one hundred percent type-one water 
solutions. The ~·s of the 500.0 ul solutions are greatest in all. 
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cases. In order to complete a densitometer cross-scan of these plates, 
realignment was necessary at the 300.0 ul and 500.0 ul saline solutions. 
The dark spot Rf's are above the 0.3-0.7 range for two of the 500.0 ul 
saline solutions. 
Tylosin Tartrate Saline Solution Spot Diffusion 
Saline concentration of the application solution influences the 
tylosin tartrate spot diameter. This phenomenon was examined by 
applying various saline concentrations with an identical tylosin 
tartrate amount ta a Whatman LKC 18 F TLC plate. Table 12 is a summary of 
the dark spot diameters. The spat diameters tend to increase as the 
viscosity of the resultant solution decreases. 
The one hundred percent type-one water and 100.0 ul saline 
·Solutions have comparable spot diameters. Spot diameters increase for 
the 300.0 ul saline solutions and are greatest for 500.0 ul saline 
solutions. The spot diameters of the mammalian Ringer's solution 
samples in Figure 20 are comparable to the values of the 500.0 ul saline· 
' solutions in Table 12. In Figure 20, an amount of drug is present in 10 
ul of type-one water at five different concentrations, and these are 
spotted on the TLC plate (left side). Also, the same levels of drug are 
present in 10 ul of Ringer's solution which are spotted on the TLC plate 
(right side). In Table 12, the solutions are dried down in a one-dram 
vial, and then specific amounts of type-one water are added to the salts 
and drug deposH. For the 500. 0 ul cases in Table 12, spot diamet.ers 
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TABLE 12. Variation of dark spot diameter due to saline concentration 
differences of the application solution. 
TLC plate 
1 
1 
1 
1 
2 
2 
2 
2 
3 
3 
3 
3 
Amount of tylosin 
tartrate 
(ug) 
2.0 
2.0 
2.0 
2.0 
3.0 
3.0 
3.0 
3.0 
4.0 
4.0 
4.0 
4.0 
Amount of type-one 
water added to the 
salts of 2 ml of 
Ringer's solution 
(ul) 
100% type-one water 
100.0 
300.0 
500.0 
100% type-one water 
100.0 
300.0 
500.0 
100% type-one water 
100.0 
300.0 
500.0 
Dark spot 
diameter, 
(mm) 
2.5 
3.0 
3.5 
5.0 
2.5 
3.0 
4.0 
4.5 
2.5 
3.0 
3.5 
4.5 
are recorded and are similar to those for the Ringer's solution cases in 
Figure 20. Thus, the saline concentrations for the Ringer's solution 
samples spotted and indicated in Figure 20 were lower (by 1/4) than that 
of the 500.0 ul cases of Table 12, and the spot diameters were about the 
same (approximately 4.8 mm compared to 4.5 to 5.0 mm from Table 12). 
Therefore, dilution experiments greater than 500.0 ul were not conducted 
or reported for the series listed in Table 12. 
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Statistical Evaluation of the TLC Quantitative Analysis of Tylosin 
Tartrate 
Variability and reliability of the TLC quantitative analysis of tylosin 
tartrate type-one aqueous solutions 
The variability and reliability of the TLC quantitative analysis of 
tylosin tartrate were evaluated by the application of seven identical 
amounts of tylosiri tartrate, in a type-one aqueous solution, to a 
Whatman LKC 18 F TLC plate and subsequent characterization. The average 
weight of peak data obtained from the TLC quantitative analysis are 
contained in Appendix A. 
A statistical analysis of the data contained in Appendix A is shown . 
in Table 13. Due to variations among the TLC plates, the results from 
different plates may be compared only if the data are normalized. The 
coefficient of variance (standard deviation/mean) is a normalized value. 
An examination of the coefficient of variance (Table 13) indicates that 
there is less variability for the 0.9-10.0 ug range than the 0.2-0.8 ug 
range. '£his pattern is expected since a steady reduction in contrast 
between sample-spot and background occurs as the amount of tylosin 
tartrate decreases. 
Linearity of the relationship between average weight of peak and tylosih 
tartrate amount for type-one aqueous solutions 
TLC quantitative analysis relies upon the linear relationship 
between average weight of peak and tylosin tartrate amount for the 
quantitation of unknown amounts of tylosin tartrate. The linearity of 
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TABLE 13. Variability and reliability of the TLC quantitative analysis 
of tylosin.tartrate. 
I 
I 
Standard 
Maximum Minimum Mean deviation 
TLC Amount of average average average of average Coefficient 
plate tylosin weight weight weight weight of 
tartrate of peak of peak of peak of peak Variance 
(ug) (gm) (gm) (gm} (gm} 
1 0.2 0.011 0.004 0.007 0.002 0.286 
2 0.3 0.011 0.008 0.010 0.001 0.100 
3 0.4 0.024 0.013 0.018 0.004 0.222 
4 0.5 0.024 0.017 0.021 0.003 0.143 
5 0.6 0.033 0.019 0.027 0.005 0.185 
6 0.7 0.023 0.013 0.017 0.003 0.176 
7 0.8 0.014 0.009 0.011 0.002 0.182 
8 0.9 0.023 0.017 0.019 0.002 0.105 
9 LO 0.015 0.010 0.013 0.001 0.077 
10 2.0 0.019 0.017 0.018 0.001 0.056 
11 3.0 0.056 0.049 0.052 0.003 0.058 
12 4.0 0.016 0.012 0.014 0.001 0.071 
13 5.0 0.031 0.022 0.028 0.003 0.105 
14 6.0 0.036 0.030 0.033 0.002 0.061 
15 7.0 0.037 0.030 0.035 0.003 0.086 
16 8.0 0.049 0.037 0.044 0.004 0.091 
17 9.0 0.071 0.060 0.067 0.004 0.060 
18 10.0 0.095 0.073 0.087 0.007 0.080 
the relationship was evaluated by dividing the tylosin tartrate type-one 
aqueous solution standards into three groups. Each group of standards 
was applied to five Whatman LKC 18 F TLC plates. The average weight of 
peak data obtained from the TLC quantitative analysis are contained in 
Appendix B. 
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Regression line calculations were conducted utilizing the data in 
Appendix B. The statistical summary in Table 14 shows the linearity of 
the experimental data in Appendix B. 
TABLE 14. Linearity of the relationship between average weight of peak 
and tylosin tartrate amount. 
Range of tylosin Coefficient of Standard 
TLC plate tartrate determination error x 
(ug) (r2) 10-3 
l 0.1 - 0.7 0.984 0.915 
2 0.1 - 0.7 0.673 2.014 
3 0.1 - 0.7 0.898 1.007 
4 0.1 - 0.7 0. 726 2.614 
5 0.1 - 0.7 0.707 2.165 
6 0.8 - 5.0 0.%7 7.288 
7 0.8 - 5.0 0.995 2.577 
8 0.8 - 5.0 0.991 2.161 
9 0.8 - 5.0 0.981 2.311 
10 0.8 - 5.0 0.985 6.034 
11 4.0 - 10.0 0.992 1.121 
12 4.0 - 10.0 0.951 3.052 
13 4.0 - 10.0 0.986 1.122 
14 4.0 - 10.0 0.931 2.606 
15 4.0 - 10.0 0.997 0.627 
The coefficient of determination (r2) in Table 14 indicates how 
well the data fit a linear regression calculation. An r2 value of one 
denotes a perfect linear relationship, and an r2 value of zero means 
that no linear relationship exists. The data in Table 14 indicate 
greater deviation from a linear relationship for the 0.1-0.7 ug group 
73 
than for the other two groups. This correlates well with the results of 
the variability and reliability study discussed above. 
Variability and reliability of the TLC quantitative analysis of tylosin 
tartrate saline solutions 
The saline concentration of the application solution affects spot 
diameter and Rf, which in turn influence the densitometric analysis. 
The variability and reliability of the TLC quantitative analysis of 
tylosin tartrate due to different saline concentrations were examined by 
applying various saline concentrations with an identical tylosin 
tartrate amount to a Whatman LKC 18 F TLC plate. The average weight of 
peak data obtained from the TLC quantitative analysis are in Appendix C. 
A statistical analysis of the data in Appendix C is shown in Table 
15. The coefficients of variance in Table 15 are greater than the 
coefficients of variance for identical amounts of tylosin tartrate in 
Table 13. 
The coefficients of variance in Table 15 indicate the maximum 
variability of a dry release-experiment sample solubilized with 500.0 ul 
of type-one water. The data in Appendix C indicate a direct 
relationship between peak weight variability and amount of type-one 
water. Therefore, less variability is expected for release experiment 
samples resolubilized with smaller amounts of type-one water. 
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TABLE 15. Variability and reliability of the TLC quantitative analysis 
of tylosin tartrate for 500. 0 ul saline solutions .. 
Standard 
Maximum Minimum Mean deviation 
TLC Amount of average average average of average Coefficient 
plate tylosin weight weight weight weight of 
tartrate of peak of peak of peak of peak Variance 
(ug) (gm) (gm) (gm) (gm) 
1 2.0 0.014 0.008 0.011 0.002 0.182 
2 3.0 0.019 0.014 0.017 0.002 0.118 
3 4.0 0.024 0.016 0.019 0.002 0.105 
Tylosin Tartrate·Release-Experiment 
Production of the 90:10 MMA/2-HEMA copolymer films 
After the ten hour mixing and heating period, a cloudy solution 
that occasionally contained gel material formed. The dried films were 
clear, with some regions of small air bubbles. Although flexible, the 
films broke abruptly when bent to an angle of approximately ninety 
degrees. Films soaked in water became cloudy and were easily cut into 
disks with a corkborer; by comparison, dry films broke when cut. A 
total of 17'5 disks were produced from film regions without air bubbles. 
Disk thickness ranged from 0.097-0.419 mm. Thirty disks of minimum 
thickness, but within a ± 10% tolerance, were required for the release-
experiment. Thirty-one disks with a 0.223 ± 10% mm thickness were 
available; therefore, they were selected as the control membranes. 
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Figure 21 shows the film surface cast in contact with glass. The 
surface is smooth with no visible pores. The film surface cast in 
contact with air is also smooth with no visible pores (Figure 22). 
Production of the poly (lactic acid)-tylosin tartrate matrix 
.,A poly (lactic acid)-tylosin tartrate matrix was utilized for the 
inner layer of controlled-release systems 32A-E. Scanning electron 
microscopy revealed that tylosin tartrate formed a layer between the 
poly (lactic acid) film and the siliconized, plain-glass slide (room 
temperature production). Figure 23 shows the surface cast in contact 
with glass of the matrix that was prepared at room temperature, and the 
micrograph in Figure 24 is the corresponding surface of a poly (lactic 
acid) film produced in the identical manner, but without tylosin 
'tartrate. Immersion of the poly (lactic acid)-tylosin tartrate matrix, 
in a 37°C mammalian Ringer's solution for thirty hours, removed the 
tylosin tartrate layer (Figure 25). The cold production method appears 
to keep the tylosin tartrate within the matrix. Figure 26 shows the 
surface cast in contact with glass of a poly (lactic acid)-tylosin 
tartrate matrix produced by the cold method, and Figure 27 is the same 
surface after a thirty-hour immersion in 37°C mammalian Ringer's 
solution. 
This SEM analysis indicated that the cold production poly (lactic 
acid)-tylosin tartrate matrix would be the more favorable drug 
reservoir; therefore, it was utilized in controlled-release systems 32A-
E. 
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FIGURE 21. 90:10 MMA/2-HEMA cast film. Surface in contact with glass 
(scale bar=40 um). 25 keV. 
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FIGURE 22. 90:10 MMA/2-HEMA cast film. Surface in contact with air 
(scale bar=40 um). 25 keV. 
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FIGURE 23. Poly (lactic acid)-tylosin tartrate matrix cast at room 
temperature. Surface in contact with glass (scale 
bar=lOOum). 25 keV. 
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FIGURE 24. Poly (lactic acid) film cast at room temperature. Surface 
in contact with glass (scale bar=lOO um). 25 keV. 
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FIGURE 25. Poly (lactic acid}-tylosin tartrate cast matrix (prepared at 
room temperature) after immersion in a Ringer's solution at 
37°C for thirty hours. Surface cast in contact with glass 
(scale bar=lOO um). 25 keV. 
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FIGURE 26. Poly (lactic acid)-tylosin tartrate cast matrix (cold 
p~oduction method). Surface in contact with glass (scale 
bar=lOO um). 25 keV. 
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FIGURE 27. Poly (lactic acid)-tylosin tartrate cast matrix (cold 
production method) after immersion in a Ringer's solution at 
37°C for thirty hours. Surface cast in contact with glass 
(scale bar=lOO um). 25 keV. 
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The white films were highly flexible. They were cut into disks 
with a corkborer, and with care, they did not tear. The eight disks 
were ·0.127 ± 10% mm thick, and the weight of the five utilized for 
controlled-release systems 32A-E were 0.0084, 0.0082, 0.0081, 0.0084, 
and 0.0082 gm, respectively. 
Production of the controlled-release systems 
·The 90:10 MMA/2-HEMA copolymer solution· effectively joined the 
systems together since no perforations were found during the 40X 
stereomicroscopic examination. The fifty-five gram weight applied to 
the top slide held the edges of the 90: IO MMA/2-HEMA· films together 
during productfon. In some cases the joining solution flowed· into the 
system, and in 0°thers the solution ·flowed out. Table 16 summarizes the 
post-production system characteristics. Controlled-release systems 32A-
E and 33C were flat while the remaining systems were saucer-shaped due 
to the mass of tylosin tartrate ·1ocated in the center of the device. 
Tylosin tartrate mixed to varying degrees with the joining solution of 
systems 34A-E due-to the physical size limitation of the device. 
Tylosin tartrate release-experiment 
The experimental process was conducted as explained in the 
procedures section. At the beginning of the experiment, the'controlled-
release systems were totally dry; however, at the first collection 
period and throughout the remainder of the experiment, mammalian· 
Ringer's solution filled the bubbles of 33A-B, D-E, and 34A-E. Fluid 
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TABLE 16. Characteristics of the controlled-release systems after 
production. 
Controlled-release system 
32 A-E 
33 A-B, D-E 
33 c 
34 A-E 
Characteristics 
Systems are flat with a total thickness 
equal to the thickness of the three 
layers. 
Systems are flat with the exception of 
a 5.0 mm diameter bubble in the center 
of the devices containing tylosin 
tartrate. The bubble creates a saucer-
shape with approximately 1.0· mm center 
thickness and 0.5 mm edge thickness. 
System is flat with a total thickness 
of approximately 0.8 mm. The tylosin 
tartrate is mixed with the joining 
solution. 
systems are flat with the exception of a 
9.0 mm bubble in the center of the device 
containing tylosin tartrate. The bubble 
creates a saucer-shape with approximately 
2.0 mm center thickness and 1.0 mm edge 
thickness. Tylosin tartrate mixed with 
the joining solution. 
was not visible in 32A-E and 33C. The controlled-release systems did 
not appear to swell; rather, fluid filled the available space within the 
devices. 
Samples collected in accordance with the procedure were totally 
evaporated in approximately seventy-two hours. Thin layer 
chromatography was utilized to detect and quantify the amount of tylosin 
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tartrate in each sample. The dark spot of the tylosin tartrate pattern 
was utilized for the densitometer scan. Due to dark spot tailing at 
5.0-10.0 ug quantities of tylosin tartrate, all samples from the tylosin 
tartrate release-experiment were diluted to a tylosin tartrate 
concentration below 5 ug/10 ul before scanning. Appendices D-R contain' 
data from controlled-release systems 32A-34E, respectively. The data 
include regression line data number, total volume of release-experiment 
sample, weight of peak #1, weight of peak #2, average weight of peak, 
amount of tylosin tartrate in the 10' ul volume applied to the TLC plate, 
and the amount of tylosin tartrate in the total sample volume. In the 
release-experiment analysis, known concentrations of tylosin tartrate in 
type-one aqueous solution were utilized to calculate the regression line 
equation. These data are contained in Appendix S, and are related to 
the data in Appendices D-R by the regression line data number. 
The cumulative tylosin tartrate release data are plotted in Figures 
28-42 and the results are summarized in Table 17. A period of zero-
order release occurred for most of the controlled-release systems. This 
region is shown in Figures 28-31 and 33-42 by a straight line. Data 
points are not plotted for those samples that failed to produce spots on 
the TLC plate although lines are shown for ranges including these 
samples. Some of these sampling periods are too close to provide 
samples with detectable amounts of drug. The figures where this 
situation occurs exhibit a low slope, and it is likely that the variance 
on any particular sampling may yield a case where the drug is not able 
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FIGURE 28. Cumulative tylosin tartrate released versus time for system 
32A. No spot developed on the TLC plate for the samples 
collected at 32 and 36 hours 
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FIGURE 29. Cumulative tylosin tartrate released versus time for system 
32B. No spot developed on the TLC plate for the samples 
collected at 80, 84, 96, 100, 104, and 108 hours 
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FIGURE 30. Cumulative tylosin tartrate released versus time for system 
32C. No 'spot developed on the TLC plate for the samples 
collected at 56, 60, 72, 76, 80, 84, 100, 104, 108, and 120 
hours 
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FIGURE 31. Cumulative tylosin tartrate released versus time for system 
320. No spot developed on the TLC plate for the samples 
collected at 24, 28, 32, 36, 48, 52, 56, 60, 72, 80, 84, 96, 
100, 104, 108, and 120 hours 
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FIGURE 32. Cumulative tylosin tartrate released versus time for system 
32E. No spot developed on the TLC plate for the samples 
collected at 36, 52, 56, 60, 72, 76., 80, 84, 96, 100, 104, 
108, and 120 hours . 
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FIGURE 33. cumulative tylosin tartrate released versus time for system 
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FIGURE 34. Cumulative tylosin tartrate released versus time for system 
33B. No spot developed on the TLC plate for the sample 
collected at B hours 
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FIGURE 35. Cumulative tylosin tartrate released versus time for system 
33C. No spot developed on the TLC plate for the sample 
collected at 80 hours 
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FIGURE 36. ·Cumulative tylosin tartrate released versus time for system 
330. No spot developed on the TLC plate for the sample 
collected at 60 hours 
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FIGURE 37. Cumulative tylosin tartrate released versus time for system 
33E. No spot developed on the TLC plate for the samples 
collected at 32 and 36 hours 
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FIGURE 38. Cumulative tylosin tartrate releas~d versus time for system 
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FIGURE 39. Cumulative tylosin tartrate released versus time for system 
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FIGURE 40. Cumulative tylosin tartrate release versus time for system 
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·FIGURE 41. Cumulative tylosin tartrate release versus time for system 
340 
99 
30000 
eeA A A 
0 'i 
~ 
00 
3 24000 
18000 
12000 
6000 
20 40 60 BO 100 120 
TIME (hours) 
FIGURE 42. Cumulative tylosin tartrate released versus time for system 
34E 
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TABLE 17. Results of the tylosin tartrate release-experiment. 
Sample Number Linear Time of Release Rate Release over Total 
of release linear over linear total time original 
data rate release range drug 
points range rate loading 
(hr) (hr) (ug/hr) (ug) (ug) 
32A 11 48-104 56 0.9 611.8 4840 
32B 7 48-120 72 0.4 576.1 4840 
32C 4 32-96 64 0.1 362.2 4840 
320 2 12-76 64 0.1 495.1 4840 
32E 870.l 4840 
33A 16 28-120 92 0.6 347.0 5000 
33B 15 32-120 88 0.7 408.8 5000 
33C 12 48-120 72 0.3 283.6 5000 
330 16 24-120 96 0.2 136.8 5000 
33E 15 24-120 96 0.8 736.7 5000 
34A 14 36-120 84 6.0 31729.8 50000 
34B 14 36-120 84 33.3 32619.0 50000 
34C 12 12-80 68 1.0 991.8 50000 
340 8 48-84 36 10.0 1316.7 50000 
34E 15 32-120 88 20.3 25927.4 50000 
to be detected. However, an overall trend in these figures has been 
indicated. These samples contained less than 2.0 ug of tylosin 
tartrate, and the collection times are noted in the figure caption. The 
duration, rate of tylosin tartrate release, and number of data points 
for the zero-order release period are tabulated in Table 17. 
The tylosin tartrate release rate required for an ocular 
controlled-release system varies in accordance with the lachrymal flow 
rate. Hoffman and Spadbrow (1978) and Slatter and Edwards (1982) 
.. ·· determined bovine lachrymal flow rates, and Table 18 contains the 
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TABLE 18. Tylosin release rate required with lacryrnal flow variation. 
Lacryrnal flow 
(ml/hr) 
0.1 
0.3 
0.5 
0.7 
0.9 
1.1 
1.3 
1. 5 
1. 7 
1.9 
2.1 
2.3 
2.5 
2.7 
2.9 
3.1 
3.3 
3.5 
3.7 
3.9 
Time required to 
produce a 0.5 ml 
tear volume 
(min) 
300.0 
100.0 
60.0 
42.9 
33.3 
27 .3 
23.l 
20.0 
17.7 
15.8 
14.3 
13.0 
12.0 
11.l 
10.3 
9.7 
9.1 
8.6 
8.1 
7.7 
Tylosin release rate 
required 
(ug/hr) 
0.063 
0.189 
0.315 
0.441 
0.568 
0.692 
0.818 
0.945 
1.068 
1.196 
1.322 
1.454 
1.575 
1. 703 
1.835 
1.948 
2.077 
2.198 
2.333 
2.455 
required tylosin tartrate release rate over the range of their reported 
data. The calculations utilized to produce Table 18 are explained by 
the following example. A lachrymal flow rate of 0.5 ml/hr will produce 
the 0.5 ml tear volume in sixty minutes. The minimum inhibitory 
concentration to suppress bacterial colonization for the bacterial 
strains of interest when studied for tylosin tartrate is 0.63 ug/ml. 
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(R. F. Rosenbusch, personal comrnunication.)1 Therefore, 0.315 ug of 
tylosin tartrate must be contained in the eye. Since the tear volume 
is replaced every hour, the release rate must be 0.315 ug/hr. 
The required tylosin tartrate release rate ranges from 0.063-2.455 
ug/hr (Figure 18). Controlled-release systems 32A-E, 33A-E, and 34C 
produced release rates ranging from 0.1-0.9 ug/hr, and controlled-
release systems 34A, 34B, 340, and 34E produced tylosin tartrate release 
rates in excess of 2.455 ug/hr. 
There are wide variations in the release rate of similar 
controlled-release systems. The results of a post-experiment 
examination (at 40X) of the controlled-release systems (Table 19) 
obtained by using a stereomicroscope may account for these differences. 
Each controlled-release system was first examined for external security, 
and then the device was broken open to examine the interior 
characteristics. 
A comparison of the data in Table 17 and Table 19 indicate that the 
release rates of the tylosin tartrate release-experiments correlate well. 
with the post-experiment characteristics. This relationship will be 
examined in the discussion. 
1 Veterinary Medical Research Institute, Iowa State University, 
Ames, Iowaa 
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TABLE 19. Post-experiment characteristics of the controlled-release 
systems 
Controlled-release system 
32A 
320 
32B 
32C 
32E 
33A 
338 
33C 
330 
Characteristics 
Systems are sealed around the edges, 
center of the devices are open, and the 
release area may be approximated as a 
10.0 mm diameter circle. No evidence 
of residual tylosin tartrate. 
System is sealed around the edges, 
center of the device is open, and the 
release area may be approximated as a 
12.0 mm diameter circle. No evidence 
of residual tylosin tartrate. 
System is totally sealed by the joining 
solution. The inward movement of the 
joining solution has thickened the 
release membranes. No evidence of 
residual tylosin tartrate. 
System is sealed around the edges, 
center of the device is open, and the 
release area may be approximated as a 
14.0 mm diameter circle. No evidence 
of residual tylosin tartrate. 
Systems are totally sealed by the 
joining solution except for the 5.0 mm 
diameter bubble that contained tylosin 
tartrate. No evidence of residual 
tylosin tartrate. 
System is totally sealed by the joining 
solution. No evidence of residual 
tylosin tartrate. 
System is totally sealed by the joining 
solution except for the 2.0 mm diameter 
bubble that contained tylosin tartrate. 
The bubble is surrounded by the faint 
yellow color of tylosin tartrate residue. 
Table 19 (Continued) 
Controlled-release system 
33E 
34A 
348 
34C 
340 
34E 
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Characteristics 
system is totally sealed by the joining ' . solution except for the 4.0 mm diameter 
bubble that contained tylosin tartrate. 
No evidence of residual tylosin tartrate. 
Systems are totally sealed by the joining 
solution except for the 10.0 mm diameter 
bubble that contained tylosin tartrate. 
The bubble is surrounded by the faint 
yellow color of tylosin tartrate residue. 
System is totally sealed by the joining 
solution except for the 6.0 mm diameter 
bubble that contained tylosin tartrate. 
The bubble is surrounded by the faint 
yellow color of tylosin tartrate, and 
yellow particulate matter is dispersed 
in the joining solution. 
System is totally sealed by the joining 
solution except for the 9.0 mm diameter 
bubble that contained tylosin tartrate. 
The bubble is surrounded by the faint 
yellow color of tylosin tartrate, 
and yellow particulate matter is 
dispersed in the joining solution. 
System is totally sealed by the joining 
solution except for the 6.0 mm diameter 
bubble that contained tylosin tartrate. 
The bubble is surrounded by the faint 
yellow color of tylosin tartrate, and a 
small amount of yellow particulate 
matter is dispersed in the joining 
solution. 
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DISCUSSION 
TLC Quantitative Analysis of Tylosin Tartrate 
Touchstone and Dobbins (1978) reported that most densitometric 
methods resulted in sensitivities from 0.1 ng to 10.0 ug and 
coefficients of variance from one to five percent. Only one literature 
reference was found for a study that utilized TLC to detect tylosin 
tartrate (a sensitivity in the range of 2.0-4.0 ug was reported); 
however, direct quantitative analysis was not conducted in that study 
(Debackere and Baeten, 1971). 
In the current study, a sensitivity of 0.2 ug of tylosin tartrate 
was achieved. Samples in the range of 0.2-0.8 ug produced coefficients 
of variance from 10.0-28.6 percent when applied as a type-one aqueous 
solution. Samples from 0.9-10.0 ug had coefficients of variance from 
5.6-10.5 percent when applied as a type-one aqueous solution. There is 
an inverse relationship between spot intensity and variability. 
Faint spots produce higher coefficients of variance than intense 
spots. The spot-intensity produced by a particular amount of tylosin 
tartrate varies from plate to plate; consequently, the co~fficient of 
variance would be affected accordingly. For example, the 0.3 ug and the 
0.9 ug tylosin tartrate samples in Table 13 have similar spot 
intensities, and their coefficients of variance differ by 0.5 percent. 
The application process is potentially a large source of error. 
This study utilized a single-spot apparatus; however, multi-spot devices 
are commercially available. With a multi-spot apparatus, all of the 
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samples on a TLC plate are applied simultaneously under identical 
environmental conditions. 
The saline concentration of· the application solution affects its 
viscosity, and the viscosity of the application solution influences spot 
diameter and Rf. In this study, the 10.0 ul amounts applied to the TLC 
plate were applied in approximately 3.0 ul increments. A low 
concentation saline solution has less viscosity than a high 
concentration saline solution; therefore, the 3.0 ul amount 
(approximate) of low saline concentration will spread more when applied 
to the TLC plate. The low concentration saline solution spreads the 
tylosin tartrate over a greater area compared with the high 
concentration saline solution. This results in greater Rf values since· 
the developing solution acts over the larger spot area, facilitating 
sample movement. Larger spots are more diffuse; consequently, the 
coefficients of variance are greater. The results of this study 
indicate that a 500.0 ul amount of type-one water containing the salts 
from 2.0 ml of mammalian Ringer's solution yielded coefficients of 
variance twice as large as those for pure type-one water. It was also 
found that a 100.0 ul amount of type-one water containing the salts from 
2.0 ml of mammalian Ringer's solution produced spot diameters and Rf 
values comparable to those for pure type-one water. The salts in an 
application solution are retained by the preadsorbent layer of the 
Whatman LKC 18 F TLC plate (Sherma, 1982); therefore, aqueous saline 
solutions may be applied directly to the plate without extraction. To 
reduce spot diameter and stabalize Rf' the saline concentration of all 
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application solutions could be increased to the concentration of the 
100.0 ul saline solution. This would reduce the saline solution 
coefficients of variance values to those of the pure type-one water 
solutions and the extraction process would still be unnecessary. 
Thin layer chromatography utilizes physical and chemical properties 
to separate a sample into components. The TLC process produced a two-
spot pattern for 0.2-0.7 ug amounts of tylosin tartrate and a three-spot 
pattern for 0.8-10.0 ug amounts of tylosin tartrate. The visualization 
spray (ten percent by volume sulfuric acid in methanol) reacts with 
organic materials to produce a dark area. In aqueous solution, tylosin 
tartrate separates into its component ions. Tylosin is amphipathic. 
The tartrate group is polar. The developing solution is polar relative 
to the Whatman LKC 18F TLC plate; therefore, the tartrate favors the 
developing solution and moves easily with the developing solution. For 
this reason, it is hypothesized that the top band of greatest R is due 
to the tartrate. The dark spot utilized for the densitometric analysis 
of tylosin appears at an R value indicative of an amphipathic compound. 
Polar regions permit movement by the developing solution, but nonpolar 
regions cause tylosin to be retained by the TLC plate. The composition 
of the light, diffuse spot visible for 0.8-10.0 ug amounts of tylosin 
tartrate may be due to fragmentation of the tylosin molecule or other 
organic impurities. (H. M. Stahr, personal communication.)1 Subsequent 
controlled-release studies will utilize lachrymal fluid as the medium. 
1 Veterinary Diagnostic Laboratory, Iowa State University, Ames, 
Iowa. 
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It is anticipated that the TLC process will separate tylosin from the 
proteins, enzymes, and other contaminants within lachrymal fluid. This 
capability is a definite advantage of the TLC process. 
The TLC quantitative analysis procedure utilized in this study was 
time-consuming, but a multi-spotting apparatus would significantly 
reduce sample application times and an electronic digital integrator 
would eliminate the "cut and weigh" method of peak-area measurement. 
Additionally, these two modifications are expected to reduce the 
coefficient of variance. 
TLC quantitative analysis relies upon the linear relationship 
between average weight of peak and tylosin tartrate amount for the 
quantitation of unknown amounts of tylosin tartrate. The experimentally 
determined coefficient of determination values (r2) were close to 1.0. 
This indicates that a high degree of linearity was achieved. 
Production of the Controlled-Release Systems 
The control membrane thickness affects the rate of drug release 
from a system (Olanoff and Anderson, 1979). A large number of 90:10 
MMA/2-HEMA films were produced in order to obtain the thirty disks 
needed for the controlled-release systems. The 0.223 ± 10% mm thickness 
utilized for this report was the minimum thickness available that 
provided thirty disks. The viscosity of the 90:10 MMA/2-HEMA solution 
limited the production of thinner films; and larger amounts of acetone 
and dimethylformamide resulted in films with a significant increase in 
the number and the size of entrapped air bubbles. olanoff and Anderson 
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(1979) utilized acetone and dioxane solvents to produce a trilaminar 
insert, and this choice of solvent might offer somewhat improved 
fabrication results (a preliminary study indicated that good films can 
be made). 
The post-experiment examination of the controlled-release systems 
indicated the need for better quality control of the assembly process. 
The 55.0 gm weight on the top glass-slide ensured that the.edges of the 
two 90:10 MMA/2-HEMA disks remained in contact with the joining solution 
during fabrication. This was necessary because the disks were not 
always perfectly flat. The weight also caused the joining solution to. 
flow from its location on the disk perimeter to the interior or exterior 
of the system. A possible method of producing flat disks is to place 
water soaked disks between two, weighted, glass slides that hold the 
disks flat. When the room temperature evaporation process is complete, 
the disks should be flat and rigid. The 20G-1 needle utilized for 
joining solution application was the smallest gauge needle that 
permitted passage of the 90:10 MMA/2-HEMA solution. A less viscous 
joining solution would pass through a narrower bore needle and permit 
closer regulation of the joining solution quantity applied to the 
perimeter of the 90:10 MMA/2-HEMA disk. 
The poly (lactic acid)-tylosin tartrate matrix (32A-E) and the 5.0 
mg of tylosin tartrate within systems (33A-E) were easily retained by 
the devices. Controlled-release systems 34A-E contained 50.0 mg of 
tylosin tartrate. This amount of drug filled the system and resulted in 
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extensive intermixing of the drug and joining solution in some devices. 
Therefore, smaller amounts of drug loading are recommended for devices 
of this size. 
Tylosin Tartrate Release-Experiment 
The dark spot diameters reported in Table 12 and the diameters of 
the dark spots from tylosin tartrate mammalian Ringer's solutions in 
Figure 20 indicate that spot diameter increases with decreased saline 
concentration between the pure type-one water and 500.0 ul saline 
solution; however, there is no significant difference in spot diameter 
due to saline concentration between 500.0 ul saline solutions and 
mammalian Ringer's solutions. Three hundred samples were collected 
during the release-experiment and dried. Forty-five samples were 
resolubilized with 500.0 ul or more of type-one water, 191 samples were 
resolubilized with 100.0 ul of type-one water, and sixty-four samples 
were resolubilized with intermediate amounts of type-one water. The 
maximum expected coefficient of variance occurs for samples 
resolubilized with 500.0 ul or more of type-one water. The samples 
diluted with 500.0 ul or more of type-one water produced tylosin 
tartrate spots in the range of 0.9-5.0 ug. These samples represent 
dried salts and drug to which type-one water is added. Aqueous 
solutions in this range produced coefficients of variance of 5.6-10.5 
percent (Table 13); therefore, coefficients of variance of 11.2-21.0 
percent are expected for these release samples (based on the 
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coefficients of variance in Table 15 being approximately double those in 
Table 13). The samples diluted with 100.0 ul of type-one water have 
coefficients of variance similar to those for the aqueous solutions in 
Table 13 (0.2-0.8 ug, 10.0-28.6 percent; 0.9-5.0 ug, 5.6-10.5 percent). 
The samples diluted with intermediate amounts of type-one water have 
coefficients of variance between these two extremes. 
These coefficients of variance are greater than the one to five 
percent values reported in most densitometic methods (Touchstone and 
Dobbins, 1978). However, the approximate release rates of the 
controlled-release systems can be determined. These release rates can 
be compared with the release rates required to maintain the minimum 
inhibitory concentration of tylosin tartrate, and this comparison can be 
utilized as a basis both for improving release systems and for 
developing prototype units for animal trials. 
Olanoff and Anderson (1979) found that the tetracycline release 
rate from a 63:37 MMA/2-HEMA matrix covered with a 98:2 MMA/2-HEMA 
coating was a function of general device geometry, control membrane 
thickness, disk surface area, level of core reservoir drug loading, and 
copolymer composition of the membrane coating. All of the controlled-
release systems in this study have the same general geometry and control 
membrane composition; therefore, these contributory factors were not 
examined. The influence of the control membrane thickness, disk surface 
area, and level of core reservoir drug loading can be examined from the 
experimental results of this study. 
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An overall view of the systems indicates that controlled-release 
systems 32A-E and 33A-E produced zero-order release rates covering the 
lower portion of the required release rate range, and controlled-release 
systems 34A-E produced zero-order release rates exceeding the required 
release rate range. The highest zero-order release rate of ~3.3 ug/hr 
was achieved with system 34B. This amount is far below the 30 mg 
tylosin tartrate dose currently sprayed into the eye in a single 
application. Controlled-release systems, that are stored for a period 
of time before use, exhibit an initially high rate of release called the 
burst effect. This occurs because the drug has time to saturate the 
control membrane of the device (Cowsar, 1974). This phenomenon occurred 
iri all of the systems. The largest rate of drug release (2244.2 ug/hr) 
during the burst effect was from system 34B. The concentration of 
tylosin tartrate in the eye during the burst effect is gre~ter than the 
concentration in the eye during the zero-order release period; however, 
the concentration is still below the single application spray dosage 
currently utilized. Therefore, the burst effect is not a problem. In 
fact, the high release rate may be of benefit by eradicating 
contributory organisms of BIK. 
The following discussion combines the results of the post-
experiment stereomicroscopic examination and the factors outHned by. 
Olanoff and Anderson (1979) in order to develop an explanation of the 
range of release rates and release characteristics observed. 
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Controlled-release systems 32A-E contained a poly (lactic 
acid)-tylosin tartrate matrix between two 90:10 MMA/2-HEMA control 
membranes. The thickness of the control membrane and the thickness and 
weight of the inner layer were carefully regulated so similar release 
characteristics were expected. However, the release rates were 
different, and most of the variance may be attributed to the assembly 
process. After the initial burst effect, system 32A provided zero-order 
release for fifty-six hours followed by a rapid increase in the release 
rate and a return to the initial zero-order release rate. It is 
believed that the rapid increase in the release rate was due to an 
increase in the concentration of tylosin tartrate within the device. 
The drug core is a matrix device and uneven distribution of tylosin 
tartrate within the matrix could cause this phenomenon. System 328 
released a similar cumulative amount of tylosin tartrate as 32A; 
however, the zero-order release occurred at a slower rate for seventy-
two hours. Six samples during the zero-order release period did not 
contain enough tylosin tartrate for detection. The open area of system 
328 is approximated by a 12.0 mm diameter circle and that of 32A is 
approximated by a 10.0 mm diameter circle. Since 328 has the greater 
effective area of release, it would be expected to have the higher 
release rate. This apparent discrepancy may be explained by the level 
of drug loading in the core. If the concentration gradient across the 
control membrane is less, the release rate will also be less. System 
32C was completely sealed with joining solution; therefore, the 
thickness of the control membrane was greatest for this device. The 
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thicker control membrane is expected to slow the release rate, and 32C 
has one of the slowest release rates in the series (0.1 ug/hr). The 
rate of release was so low that eleven of the samples did not contain a 
sufficient quantity, of tylosin tartrate for detection. The post-
experiment characteristics of systems 32A and 320 are identical; thus, 
similar release characteristics are expected. Unfortunately, the 
release rate from 320 is nine times slower than the release rate of 32A. 
Both systems had similar control membrane thickness and effective area 
of release; thus, the variation must be associated with the level of 
drug loading in the core. System 32E released 870.l ug of tylosin 
tartrate in a forty-eight hour burst, the largest cumulative release in 
this series. System 32E was the only device that did not produce a 
per~od of zero-order release. The 14.0 mm diameter effective release 
area is the largest area in this series; thus, an increased rate of 
release would be expected, but that rate should be lower than the 
experimental values. The release pattern of 32E is indicative of a 
matrix system, not a reservoir, since there is a rapid decrease in the 
release rate versus time. Although no perforations were located in the 
sys.tern during the post-experiment analysis, a break in the control 
membrane would permit this type of release. 
Controlled-release systems 33A-E contained 5.0 mg of tylosin 
tartrate between two 90:10 MMA/2-HEMA control membranes. The thickness 
of the control membrane and the weight of tylosin were carefully 
regulated; therefore, similar release characteristics were expected. 
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However, the release rates were different, and the variance may be 
attributed to the assembly process. System 33A produced a O.G ug/hr 
zero-order release rate for ninety-two hours and released a total 
cumulative tylosin tartrate amount of 347.0 ug. The effective release 
area has a 5.0 mm diameter. Tylosin tartrate remained inside of this 
area during the assembly process, and did not intermix with the joining 
solution. The post-experiment characteristics of systems 33A and 338 
are identical; thus, similar release characteristics are expected and do 
occur. System 338 produced a 0.7 ug/hr zero-order release rate for 
eighty-eight hours and released a total cumulative tylosin. tartrate 
amount of 408.8 ug. System 33C was completely sealed, and the tylosin 
tartrate was dispersed within the joining solution. After the 
experiment, there was no evidence of tylosin residue. The thicker 
control membrane is expected to slow the release rate, and an 
experimental value of 0.3 ug/hr was obtained. System 330 contained a 
2.0 mm diameter effective release area, and the remainder of the device 
was sealed. The tylosin tartrate intermixed with the joining solution, 
and the device retained the yellow color of tylosin tartrate after the 
experiment. The intermixing of the tylosin tartrate and the joining 
solution coated the drug·particles, effectively prohibiting that drug 
amount from contributing to the concentration gradient. The 0.2 ug/hr 
zero-order release rate and the 136.8 ug amount of tylosin tartrate were 
the lowest values in this series. System 33E contained a 4.0 mm 
diameter effective release area, and the remainder of the device was 
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sealed. These physical characteristics are similar to those of 33A and 
33a; therefore, similar release characteristics are expected. The burst 
effect of system 33E released more drug than systems 33A or 338 so the 
739.0 ug cumulative release is greater. However, the ninety-six hour, 
0.8 ug/hr zero-order release rate correlates well with the values 
obtained for systems 33A and 338. 
Controlled-release systems 34A-E contained 50.0 mg of tylosin 
tartrate between two 90:10 MMA/2-HEMA control membranes. The thickness 
of the control membrane and the weight of tylosin were carefully 
regulated; thus, similar release characteristics were expected. 
However, the release rates were quite variable, and these differences 
may be attributed to the assembly process. Due to the physical size 
limitations of the controlled-release systems it was very difficult to 
prevent intermixing of the joining solution and tylosin tartrate. This 
intermixing is the primary cause of variation in the release 
characteristics for systems 34A-E. System 34A produced a 6.0 ug/hr 
zero-order release rate for eighty-four hours and released a t~tal 
cumulative tylosin tartrate amount of 31,729.8 ug. The effective 
release area has a 6.0 mm diameter. Tylosin tartrate mixed with the 
joining solution at the interface, and the device retained the faint 
yellow color of tylosin tartrate after the experiment. The post-
experiment characteristics of systems 34A and 348 are identical; thus, 
similar release characteristics are expected. System 348 produced a 
33.3 ug/hr zero-order release rate for eighty-four hours and released a 
total cumulative tylosin tartrate amount of 32,619.0 ug. Therefore, the 
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cumulative tylosin tartrate release for systems 34A and 34B are similar, 
but the release rate for system 34B is 5.6 times higher than that of 
34A. This difference cannot be explained by the post-experiment 
characteristics since the devices appeared identical. However, it is 
possible that the joining solution may have mixed with the tylosin 
tartrate to a greater extent in system 34A than in system 34B. Thus, 
the tylosin tartrate concentration gradient in system 34A would be lower 
and the release rate smaller. System 34C contained a 6.0 mm diameter 
effective release area and the remainder of the device was sealed. 
Extensive intermixing of the joining solution and tylosin tartrate 
~ccurred, and tylosin tartrate particles remained in the device after 
the experiment. This intermixing dramatically reduced the drug 
concentration gradient across the membrane. System 34C produced a 1.0 
ug/hr zero-order release rate for sixty-eight hours and released a total 
cumulative tylosin tartrate amount of 991.8 ug. System 340 had a 9.0 mm 
diameter effective release area; otherwise, its post-experiment 
characteristics were identical to those of system 34C. The intermixing 
of tylosin tartrate and joining solution is the primary factor in the 
10.0 ug/hr, thirty-six hour zero-order release rate and total cumulative 
tylosin release of 1,316.7 ug for system 340. System 34E produced a 
20.3 ug/hr zero-order release rate for eighty-eight hours and released a 
total cumulative tylosin tartrate amount of 25,927.4 ug. The effective 
release area has a 6.0 mm diameter. Some intermixing of the joining 
solution and tylosin tartrate occurred, and a few tylosin tartrate 
particles remained in the device after the experiment. This intermixing 
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was more extensive than systems 34A and 34B and less extensive than 
systems 34C and 340; therefore, intermediate release rates were expected 
and did occur. 
The release-experiment data indicate that with improved quality 
control it is possible to achieve a predictable zero-order release of 
tylosin tartrate powder from 90:10 MMA/2-HEMA reservoir devices at the 
rate needed to treat BIK. The release rates from the 33 series were not 
sufficient to cover the entire lachrymal flow range, and the release 
rates from the 34 series exceeded the required rates. Therefore, the 
optimum drug loading is between 5.0-50.0 mg. Although the devices have· 
an exterior diameter of 17.9 mm, the effective release area diameters 
were on the order of 4.0 mm for the 33 series and 7.0 mm for the 34 
series. Zero-order release is achieved by this configuration because 
the hydrophobic 90:10 MMA/2-HEMA control membrane restricts the flow of· 
water to the interior of the device. Thus, a saturated solution is 
maintained within the system for the duration of the experiment. 
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RECOMMENDATIONS FOR FURTHER RESEARCH 
Hughes and Pugh (1975) found that 42.9-44.5 mm diameter rings 
constructed of poly (vinyl chloride) tubing (with a tube outside 
diameter of 2.82, 1.65, or 0.914 mm) could be retained in the bovine eye 
for up to nineteen days. Reaction to the devices was minimal and 
consisted of increased tearing initially and increased mucous secretion 
after prolonged retention. A ring of this type could serve as the 
retaining device for a 90:10 MMA/2-HEMA-tylosin tartrate ocular 
controlled-release system. 
Figure 43 illustrates the configuration of a suggested prototype. 
The poly (vinyl chloride) tubing is first formed into a ring by 
inserting a short piece of tube with a smaller diameter into the two 
ends and joining the outer tube edges utilizing a tetrahydrofuran 
·solvent. Next, the 90:10 MMA/2-HEMA films are cut into crescents so the 
curved edge conforms to the shape of the poly (vinyl chloride) ring (See 
Figure 43). The crescents are the control membranes and should be 
totally flat for the assembly process as suggested earlier. Tylosin 
tartrate powder is weighed onto a crescent, the joining solution is 
carefully applied, and the top crescent is placed on the joining 
solution to seal the device. The results of this study indicate the 
importance of not intermixing the tylosin tartrate and joining solution, 
and controlling the size of the effective release area. When both 
crescents are dry, they are attached to the poly (vinyl chloride) ring 
with 90:10 MMA/2-HEMA joining solution. This device is designed to fit 
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Poly (vinyl chloride) 
ring 
FIGURE 43. Prototype, ocular controlled-release system 
into the conjunctival sac. Insertion is accomplished by holding the 
eyelids open and directing one side of the ring into the lateral fornix. 
The remainder of the ring is guided under the lids and onto the outer 
surface of the nictitating membrane (Hughes and Pugh, 1975). The two 
crescents would be in the upper and lower conjunctival sac. This 
configuration does not impede oxygen flow to the cornea, and the system 
would release tylosin tartrate into the region where drugs are currently 
applied (Blood and Henderson, 1979; Hughes, 1981). 
The 90,10 MMA/2-HEMA film is a fairly rigid, hydrophobic material 
and may cause ocular irritation. To reduce ocular irritation, a more 
hydrophilic hydrogel may be needed. Since tylosin tartrate is very 
soluble in water, a controlled-release system composed of hydrophilic 
hydrogel may not provide long-term release because too much water may 
flow through the hydrogel. Should this adaptation be required, tylosin 
(water solubility 5 mg/ml at 25°c) (Windholz et al., 1976) is available 
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from Elanco Products Co. (T. Matsuoka, personal communication)l, and 
could possibly be utilized in place of tylosin tartrate. 
1 Elanco .Products Co. , Indianapolis, Indiana. 
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APPENDIX A: AVERAGE WEIGHT OF PEAK DATA BASED ON SEVEN IDENTICAL 
TYLOSIN TARTRATE AMOUNTS IN TYPE-ONE AQUEOUS SOLUTION ON A TLC PLATE 
Amount of tylosin Weight of Weight of Average weight 
tartrate peak #1 peak #2 of peak 
(ug) (gm) (gm) (gm) 
0.2 0.0080 0.0078 0.0079 
0.2 0.0038 0.0038 0.0038 
0.2 0.0106 0.0108 0.0107 
0.2 0.0072 0.0078 0. 0075 
0.2 0.0062 0.0062 0.0062 
0.2 0.0066 0.0064 0.0065 
0.2 0.0064 0.0062 0.0063 
0.3 0 .0096 0.0096 0.0096 
0.3 0.0102 0.0102 0.0102 
0.3 0.0084 0.0080 0.0082 
0.3 0 .0110 0.0120 0. 0115 
0.3 0.0096 0.0104 0.0100 
0.3 0.0106 0.0108 0.0107 
0.3 0.0092 0.0084 0.0088 
0.4 0.0228 0.0206 0.0217 
0.4 0.0158 0.0152 0.0155 
0.4 0.0135 0. 0118 0.0126 
0.4 0.0238 0.0253 0.0245 
0.4 0.0158 0.0158 0.0158 
0.4 0.0148 0.0164 0.0156 
0.4 0.0174 0.0178 0.0176 
0.5 0.0232 0.0242 0.0237 
0.5 0.0207 0.0207 0.0207 
0.5 0.0224 0.0228 0.0226 
o;5 0.0181 0.0165 0.0173 
0.5 0.0174 0.0174 0.0174 
0.5 0.0230 0.0240 0.0235 
0.5 0.0200 0.0206 0.0203 
0.6 0.0188 0.0202 0.0195 
0.6 0.0287 0.0271 0.0279 
0.6 0.0230 0.0222 0.0226 
0.6 0.0284 0.0286 0.0285 
0.6 0.0241 0.0241 -0 .0241 
0.6 0.0326 0.0334 0.0330 
0.6 0.0291 0.0315 0.0303 
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Amount of tylosin Weight of Weight of Average weight 
tartrate peak #1 peak #2 of peak 
(ug) (gm) (gm) (gm) 
0.7 0.0222 0.0234 0.0228 
0.7 0.0168 0.0168 0.0168 
0.7 0.0164 0.0162 0.0163 
0.7 0.0128 0.0126 0.0127 
0.7 0.0166 0.0166 0.0166 
0.7 0.0170 0.0172 0.0171 
0.7 0.0184 0.0186 0.0185 
0.8 0.0120 0.0120 0.0120 
0.8 0.0140 0.0132 0.0136 
. 0 .8 0. 0118 0.0128 0.0123 
0.8 0.0100 0.0100 0.0100 
0.8 0.0088 0.0092 0.0090 
0.8 0.0130 0. 0132 0. 0131 
0.8 0.0100 0.0100 0.0100 
0.9 0.0224 0.0212 0.0218 
0.9 0.0179 0.0179 0.0179 
0.9 0.0204 0.0200 0.0202 
0.9 0.0228 0.0226 0.0227 
0.9 0.0176 0.0176 0.0176 
0.9 0.0196 0.0188 0.0192 
0.9 0.0163 0. 0177 0.0170 
1.0 0.0132 0.0134 0. 0133 
1.0 0.0126 0.0120 0.0123 
1.0 0.0149 0.0149 0.0149 
1.0 0.0100 0 .0110 0.0105 
1.0 0. 0118 0 .0114 0 .0116 
1.0 0.0121 0.0121 0.0121 
1.0 0.0144 0.0140 0.0142 
2.0 0.0188 0.0188 0.0188 
2.0 0.0181 0.0181 0.0181 
2.0 0.0169 0.0169 0.0169 
2.0 0.0186 0.0186 0.0186 
2.0 0.0168 0.0172 0.0170 
2.0 0.0185 0.0177 0.0181 
2.0 0.0166 0.0166 0.0166 
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Amount of tylosin Weight of Weight of Average weight 
tartrate peak #1 peak #2 of peak 
(ug) (gm) (gm) (gm) 
3.0 0.0518 0.0596 0.0557 
3.0 0.0537 0.0537 0.0537 
3.0 0.0494 0. 0478 0.0486 
3.0 0.0522 0.0524 0.0523 
3.0 0.0538 0.0536 0.0537 
3.0 0.0508 0.0500 0.0504 
3.0 0.0500 0.0498 0.0499 
4.0 0.0139 0.0137 0.0138 
4.0 0.0150 0.0142 0.0146 
4.0 0.0134 0.0130 0.0132 
4.0 0.0156 0.0158 0.0157 
4.0 0.0121 0.0125 0.0123 
4.0 0.0153 0.0155 0.0154 
4.0 0.0141 0.0143 0.0142 
5.0 0.0294 0.0290 0.0292 
5.0 0.0288 0.0288 0.0288 
5.0 0.0271 0. 0271 0.0271 
5.0 0.0305 0. 0311 0.0308 
5.0 0.0300 0.0304 0.0302 
5.0 0.0261 0.0269 0.0265 
5.0 0.0227 0.0221 0.0224 
6.0 0.0331 0.0331 0.0331 
6.0 0.0337 0.0349 0.0343 
6.0 0.0319 . 0.0315 0.0317 
6.0 0.0346 0.0344 0.0345 
6.0 0.0300 0.0308 0.0304 
6.0 0.0324 0.0322 0.0323 
6.0 0.0355 0.0359 0.0357 
7.0 0.0346 0.0352 o·.034.9 
7.0 0.0377 0.0373 0.0375 
7.0 0.0326 0.0354 0.0340 
7.0 0.0368 0.0364 0.0366 
7.0 0.0335 0.0331 0.0333 
. 7. 0 0.0375 0.0375 0.0375 
7.0 0.0313 0.0297 0.0305 
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Amount of tylosin Weight of Weight of Average weight 
tartrate peak #1 peak #2 of peak 
(ug) (gm) (gm) (gm) 
8.0 0.0455 0.0453 0.0454 
8.0 0.0470 0.0470 0.0470 
8.0 0.0491 0.0483 0.0487 
8.0 0.0415 0.0397 0.0406 
8.0 0.0459 0.0457 0.0458 
8.0 0.0452 0.0442 0.0447 
8.0 0.0372 0.0372 0.0372 
9.0 0. 0712 0.0712 0. 0712 
9.0 0.0602 0.0600 0.0601 
9.0 0.0668 0.0668 0.0668 
9.0 0.0625 0.0653 0.0639 
9.0 0.0703 0.0707 0.0705 
9.0 0.0686 0.0686 0.0686 
9.0 0.0660 0.0660 0.0660 
10.0 0.0850 0.0838 0.0844 
10.0 0.0937 0.0955 0.0946 
10.0 0.0904 0.0904 0.0904 
10.0 0.0754 0.0714 0.0734 
10.0 0.0920 0.0896 0.0908 
10.0 0.0889 0.0891 0.0890 
10.0 0.0834 0.0836 0.0835 
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APPENDIX B: AVERAGE WEIGHT OF PEAK DATA FOR THE THREE GROUPS OF TYLOSIN 
TARTRATE TYPE-ONE AQUEOUS SOLUTION STANDARDS 
TLC Plate Amount of Weight of Weight of Average weight 
tylosin peak #1 peak #2 of peak 
tartrate {gm) {gm) (gm) 
(ug) 
1 0.1 
1 0.2 0.0049 0.0051 0.0050 
l 0.3 0.0069 0.0069 0.0069 
1 0.4 0.0104 0.0092 0.0098 
l 0.5 0.0082 0.0082 0.0082 
1 0.6 0.0092 0.0082 0.0087 
1 0.7 0.0155 0.0155. 0.0155 
2 0.1 
2 0.2 0.0058 0.0056 0.0057 
2 0.3 0.0066 0.0070 0.0068 
2 0.4 0.0082 0.0082 0.0082 
2 0.5 0.0087 0.0059 0.0073 
2 0.6 0.0105 0.0105 0.0105 
2 0.7 0.0170 0.0188 0.0179 
3 0.1 
3 0.2 0.0013 0. 0013 0.0013 
3 0.3 0.0030 0.0030 0.0030 
3 0.4 0.0058 0.0066 0.0062 
3 0.5 0.0068 0.0072 0.0070 
3 0.6 0.0066 0.0068 0.0067 
3 0.7 0.0094 0.0084 0.0089 
4 0.1 
4 0.2 0.0042 0.0038 0.0040 
4 0.3 0.0060 0.0060 0.0060 
4 0.4 0.0058 0.0066 0.0062 
4 0.5 0.0068 0.0072 0.0070 
4 0.6 0.0066 0.0068 0.0067 
4 0.7 0.0094 0.0084 0.0089 
5 0.1 
5 0.2 0.0042 0.0038 0.0040 
5 0.3 0.0060 0.0060 0.0060 
5 0.4 0.0101 0.0095 0.0098 
5 0.5 0. 0118 0 .0110 0. 0114 
5 0.6 0.0087 0.0075 0.0081 
5 0.7 0 .0118 0.0124 0.0121 
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TLC Plate Amount of Weight of Weight of Average weight 
tylosin peak #1 peak #2 of peak 
tartrate (gm) (gm) (gm) 
(ug) 
6 0.8 0.0134 0. 0114 0.0124 
6 0.9 0.0096 0.0098 0.0097 
6 1.0 0.0157 0.0149 0.0153 
6 2.0 0.0328 0.0330 0.0329 
6 3.0 0.0514 0.0482 0.0498 
6 4.0 0.0673 0.0689 0.0681 
6 5.0 0.1118 0.1078 0 .1098 
7 0.8 0.0063 0.0063 0.0063 
7 0.9 0.0081 0.0083 0.0082 
7 1.0 0.0146 0.0154 0.0150 
7 2.0 0.0269 0.0285 0.0277 
7 3.0 0.0504 0.0476 0.0490 
7 4.0 0. 0716 0.0708 0.0712 
7 5.0 0.0938 0.0906 0.0922 
8 0.8 0.0035 0.0029 0.0032 
8 0.9 0.0055 0.0055 0.0055 
8 1.0 0.0072 0.0082 0. 0077 
8 2.0 0.0218 0.0228 0.0223 
8 3.0 0.0309 0.0313 0. 0311 
8 4.0 0.0391 0.0423 0.0407 
8 5.0 0.5360 0.0614 0.0575 
9 0.8 0.0031 0.0039 0.0035 
9 0.9 0.0072 0.0086 0.0079 
9 1.0 0. 0117 0.0107 0.0112 
9 2.0 0.0221 0.0215 0.0218 
9 3.0 0.0373 0.0367 0.0370 
9 4.0 0.0504 0.0536 0.0520 
9 5.0 0.0773 0. 0771 0. 0772 
10 0.8 0.0168 0.0184 0.0176 
10 0.9 0.0156 0.0154 0.0155 
10 1.0 0.0236 0.0248 0.0242 
10 2.0 0.0419 0.0401 0.0410 
10 3.0 0.0751 0.0787 0.0769 
10 4.0 0.0941 0.0965 0.0953 
lb 5.0 0.1359 0.1413 0 .1386 
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TLC Plate Amount of Weight of Weight of Average weight 
tylosin peak #1 peak #2 of peak 
tartrate (gm) (gm) (gm) 
(ug) 
11 4.0 0.0167 0.0155 0.0161 
11 5.0 0.0212 0.0196 0 •. 0204 
11 6.0 0.0268 0.0280 0.0274 
11 7.0 0.0348 0.0336 0.0342 
11 8.0 0.0381 0.0395 0.0388 
11 9.0 0.0436 0.0428 0.0432 
11 10.0 0.0482 0.0474 0. 0478 
12 4.0 0.0155 0.0153 0.0154 
12 5.0 0.0250 0.0224 0.0237 
12 6.0 0.0309 0.0305 0.0307 
12 7.0 0.0407 0.0383 0.0395 
. 12 8.0 0.0447 0.0435 0.0441 
12 9.0 0.0473 0.0437 0.0455 
12 10.0 0.0481 0.0507 0.0494 
13 4.0 0.0104 0.0086 0.0095 
13 5.0 0.0144 0.0138 0.0141 
13 6.0 0.0184 0.0176 0.0180 
13 7.0 0.0248 0.0250 0.0249 
13 8.0 0.0287 0.0281 0.0284 
13 9.0 0.0328 0.0308 0.0318 
13 10.0 0.0342 0.0350 0.0346 
14· 4.0 0.0169 0.0183 0.0176 
14 5.0 0.0266 0.0266 0.0266 
14 6.0 0.0319 0 .0277 . 0.0298 
14 7.0 0.0354 0.0330 0.0342 
14 8.0 0.0382 0.0378 0.0380 
14 9.0 0.0365 0.0373 0.0369 
14 10.0 0.0450 0.0466 0.0458 
15 4.0 0.0106 0 .0114 0.0110 
15 5.0 0.0170 0. 0178 0.0174 
·15 6.0 0.0214 0.0196 0.0205 
15 7.0 0.0252 0.0266 0.0259 
15 8.0 0.0307 0.0299 0.0303 
15 9.0 0.0342 0.0352 0.0347 
15 10.0 0.0381 0.0409 0.0395 
TLC 
plate 
1 
1 
1 
1 
1 
1 
1 
1 
2 
2 
2 
2 
2 
2 
2 
2 
3 
3 
3 
3 
3 
3 
3 
3 
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APPENDIK C: AVERAGE WEIGHT OF PEAK DATA FOR VARIOUS SALINE 
CONCENTRATIONS WITH IDENTICAL TYLOSIN TARTRATE AMOUNTS 
Amount of Amount of type-one Weight of Weight of Average 
tylosin water added to the peak #1 peak #2 weight 
tartrate salts of 2 ml of (gm) (gm) of peak 
(ug) Ringer's solution (gm) 
(ul) 
2.0 100% type-one water 0 .0112 0. 0112 0 .0112 
2.0 100% type-one water 0.0116 0. 0110 0 .0113 
2.0 100.0 ul 0.0080 0.0090 0.0085 
2.0 100.0 ul 0.0089 0.0091 0.0090 
2.0 300.0 ul 0.0108 0.0104 0 .0106 
2.0 300.0 ul 0.0087 0.0089 0.0088 
2.0 500.0 ul 0.0145 0.0141 0.0143 
2.0 500.0 ul 0. 01.27 0.0123 0.0125 
3.0 100% type-one water 0.0167 0.0177 0.0172 
3.0 100% type-one water 0.0171 0.0177 0.0174' 
3.0 100.0 ul 0.0158 0.0160 0.0159 
3.0 100.0 ul 0.0149 0.0141 0.0145 
3.0 300.0 ul 0.0152 0.0160 0.0156 
3.0 300.0 ul 0.0142 0.0146 0.0144 
3.0 500.0 ul 0.0191 0.0189 0.0190 
3.0 500.0 ul 0.0197 0.0181 0.0189 
4.0 100% type-one water 0.0163 0.0165 0.0164 
4.0 100% type-one water 0.0181 0 .0171 0.0176 
4.0 100.0 ul 0.0192 0.0196 0.0194 
4.0 100.0 ul 0.0179 0.0179 0.0179 
4.0 300.0 ul 0.0200 0.0196 0.0198 
4.0 300.0 ul 0.0180 0.0196 0.0188 
4.0 500.0 ul 0.0239 0.0235 0.0237 
4.0 500.0 ul 0.0226 0.0226 0.0226 .· 
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APPENDIX D: TYLOSIN TARTRATE RELEASE-EXPERIMENT 32A 
Sample Regres- Total Weight Weight Average Amount of Amount of 
number sion volume of of weight tylosin tylosin 
line of peak peak of peak tartrate tartrate 
data!' sampleb Ill #2 (gm) in in total 
(ul) (gm) (gm) 10 ul sample 
(ug) volume 
(ug) 
1 1 1090.0 0.0194 0.0180 0.0187 1.1 119.9 
2 1 590.0 0.0506 0.0502 0.0504 2.9 171.1 
3 1 190.0 0.0438 0.0474 0.0456 2.6 49.4 
4 1 100.0 0.0321 0.0321 0.0321 1.8 18.0 
5 2 100.0 0.0034 0.0032 0.0033 2.4 24.0 
6 100.0 No spot developed on the TLC plate 
7 100.0 No spot developed on the TLC plate 
8 2 100.0 0.0478 0.0480 0.0479 3.5 35.0 
9 3 100.0 0.0137 0.0145 0.0141 0.7 7.0 
10 3 100.0 0.0035 0.0035 0.0035 0.2 2.0 
11 3 100.0 0.0023 0.0017 0.0020 0.2 2.0 
12 3 100.0 0.0026 0.0026 0.0026 0.2 2.0 
13 4 100.0 0.0041 0.0039 0.0040 0.4 4.0 
14 4 100.0 0.0039 0.0029 0.0034 0.4 4.0 
15 4 100.0 0.0050 0.0042 0.0046 0.4 4.0 
16 5 190.0 0.0270 0.0284 0 .0277 1.6 30.4 
17 4 100.0 0.0033 0.0031 0.0032 0.3 3.0 
18 6 100.0 0.0065 0.0055 0.0060 0.6 6.0 
19 5 590.0 0.0327 0.0355 0.0341 2.0 118.0 
20 5 100.0 0.0203 0.0207 0.0205 1.2 12.0 
a 
See Appendix s. 
b 
Amount of type-one water added to the dried sample; this amount 
of liquid provides the drug level in 10 ul for the spotting to 
be in the range 0.2-5.0 ug of tylosin tartrate. For example, in 
sample number one, there are 119.9 ug in 1090.0 ul to give a 
detected level of 1.1 ug in 10.0 ul. 
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APPENDIX E: TYLOSIN TARTRATE RELEASE-EXPERIMENT 328 
Sample Regres- Total Weight Weight Average Amount of Amount of 
number sion volume of of weight tylosin tylosin 
line of peak peak of peak tartrate tartrate a 
data sample #1 #2 {gm) in in total 
(ul) (gm) (gm) 10 ul sample 
(ug) volume 
(ug) 
1 5 1090.0 0.0435 0.0469 0.0452 2.8 305.2 
2 7 590.0 0.0435 0.0421 0.0428 2.3 135.7 
3 7 190.0 0.0341 0.0333 0.0337 1.8 34.2 
4 7 190.0 0.0236 0.0256 0.0246 1.2 22.8 
5 6 100.0 0 .0118 0 .0116 0. 0117 1.0 10.0 
6 6 100.0 0.0145 0.0125 0.0135 1.1 11.0 
7 6 100.0 0 .0112 0. 0110 0.0106 0.9 9.0 
8 7 290.0 0.0172 0.0170 0.0171 0.8 23.2 
9 8 100.0 0.0070 0.0080 0.0075 0 .4 4.0 
10 8 100.0 0 .0110 0. 0110 0. 0110 0.5 5.0 
11 8 100.0 0.0102 0.0098 0.0100 0.5 5.0 
12 8 100.0 0.0108 0.0098 0.0103 0.5 5.0 
13 9 100.0 0.0027 0.0021 0.0024 0.2 2.0 
14 100.0 No spot developed on the TLC plate 
15 100.0 No spot developed on the TLC plate 
16 100.0 No spot developed on the TLC plate 
17 100.0 No spot developed on the TLC plate 
18 100.0 No spot developed on the TLC plate 
19 100.0 No spot developed on the TLC plate 
20 10 100 .o 0.0013 0.0015 0.0015 0.4 4.0 
asee Appendix s. 
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APPENDIX F: TYLOSIN TARTRATE RELEASE-EXPERIMENT 32C 
Sample Regres- Total Weight Weight Average Amount of Amount of 
number sion volume of of weight tylosin tylosin 
line of peak peak of peak tartrate tartrate 
data 8 sample #1 #2 (gm) in in total 
(ul) (gm) (gm) 10 ul sample 
(ug) volume 
(ug) 
1 11 1090.0 0.0300 0.0296 0.0298 1.5 163.5 
2 11 590.0 0. 0371 0.0389 0.0380 2.0 118.0 
3 11 190.0 0.0256 0.0258 0.0257 1.3 24.7 
4 11 100.0 0.0557 0.0529 0.0543 2.9 29.0 
5 12 100.0 0.0290 0.0332 0. 0311 1.5 15.0 
6 12 100.0 0.0138 0.0140 0.0390 0.6 6.0 
7 12 100.0 0.0033 0.0033 0.0033 0.2 2.0 
8 12 100.0 0.0037 0.0043 0.0040 0.2 2.0 
9 100.0 No spot developed on the TLC plate 
10 100.0 No spot developed on the TLC plate 
11 100.0 No spot developed on the TLC plate 
1°2 100.0 No spot developed on the TLC plate 
13 100.0 No spot developed on the TLC plate 
14 100.0 No spot developed on the TLC plate 
15 100.0 No spot developed on the TLC plate 
16 13 100.0 0.0024 0.0022 0.0023 0.2 2.0 
17 100.0 No spot developed on the TLC plate 
18 100.0 No spot developed on the TLC plate 
19 100.0 No spot developed on the TLC plate 
20 100.0 No spot developed on the TLC plate 
8 See Appendix S. 
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APPENDIX G: TYLOSIN TARTRATE RELEASE-EXPERIMENT 320 
Sample Regres- Total Weight Weight Average Amount of Amount of 
number sion volume of of weight tylosin tylosin 
line of peak peak of peak tartrate tartrate 
dataa sample #1 #2 (gm) in in total 
(ul) (gm) (gm) 10 ul sample 
(ug) volume 
(ug) 
1 14 1090.0 0.0615 0.0649 0.0632 4.1 446.9 
2 14 100.0 0.0168 0.0164 0.0166 1.0 10.0 
3 . 14 190.0 0.0292 0.0270 0.0281 1.8 34.2 
4 14 100.0 No spot developed on the TLC pla.te 
5 100.0 No spot developed on the TLC plate 
6 100.0 No spot developed on the TLC plate 
7 100.0 No spot developed on the TLC plate 
8 100.0 No spot developed on the TLC plate 
9 100.0 No spot developed on the TLC plate 
10 100.0 No spot developed on the TLC plate 
11 100.0 No spot developed on the TLC plate 
12 100.0 No spot developed·on the TLC plate 
13 15 100.0 0.0052 0.0040 0.0046 0.4 4.0 
14 100.0 No spot developed on the TLC plate 
15 100.0 No spot developed on the TLC plate 
16 100.0 No spot developed on the TLC plate 
17 100.0 No spot developed on the TLC plate 
18 100.0 No spot developed on the TLC plate 
19 100.0 No spot developed on the TLC plate 
20 100.0 No spot developed on the TLC plate 
asee Appendix S. 
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APPENDIX H: TYLOSIN TARTRATE RELEASE-EXPERIMENT 32E 
Sample Regres- Total Weight Weight Average Amount of Amount of 
number sion volume of of weight tylosin tylosin 
line of peak peak of peak tartrate tartrate 
dataa sample #1 #2 {gm) in in total 
(ul) (gm) {gm) 10 ul sample 
(ug) volume 
(ug) 
1 17 1090.0 0.0437 0.0435 0.0436 2.9 316.1 
2 17 590.0 0.0424 0.0450 0.0437 2.9 171.1 
3 17 190.0 0.0478 0.0472 0.0475 3.1 58.9 
4 17 190.0 0.0430 0.0428 0.0429 2.9 55.1 
5 16 100.0 0.0292 0.0280 0.0286 1. 7 17.0 
6 16 100.0 0.0177 0.0157 0.0167 1.0 10.0 
7 100.0 No spot developed on the TLC plate 
B 16 590.0 0. 0671 0.0695 0.0683 4.1 241.9 
9 100.0 No spot developed on the TLC plate 
10 100.0 No spot developed on the TLC plate 
11 100.0 No spot developed on the TLC plate 
12 100.0 No spot developed on the TLC plate 
13 100.0 No spot developed on the TLC plate 
14 100.0 No spot developed on the TLC plate 
15 100.0 No spot developed on the TLC plate 
16 100.0 No spot developed on the TLC plate 
17 100 .o No spot developed on the TLC plate 
18 100.0 No spot developed on the TLC plate 
19 100.0 No spot developed on the TLC plate 
20 100.0 No spot developed on the TLC plate 
asee Appendix s. 
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APPENDIX I: TYLOSIN TARTRATE RELEASE-EXPERIMENT 33A 
Sample Regres- Total Weight Weight Average Amount of Amount of 
number sion volume of of weight tylosin tylosin 
line of peak peak of peak tartrate tartrate 
data a sample #1 #2 (gm} in in total 
(ul} (gm) (gm) 10 ul sample 
(ug) volume 
(ug) 
1 1 490.0 0.0726 0.0706 0 .0716 4.2 205.8 
2 2 180.0 0.0336 0.0330 0.0333 2.4 43.2 
3 2 100.0 0.0286 0 .0296 0.0291 2.1 21.0 
4 2 100.0 0.0194 0.0190 0.0192 1.3 13.0 
5 3 100.0 0.0198 0.0190 0.0194 1.0 10.0 
6 4 100.0 0.0058 0.0060 0.0059 0.5 5.0 
7 5 100.0 0.0097 0.0109 0.0103 0.5 5.0 
8 6 100.0 0.0031 0.0031 0.0031 0.4 4.0 
9 7 100.0 0.0115 0. 0111 0 .0113 0.5 5.0 
10 8 100.0 0.0040 0.0044 0.0042 0.2 2.0 
11 9 100.0 0.0022 0.0022 0.0022 0.2 2.0 
12 9 100.0 0.0038 0.0036 0.0035 0.4 4.0 
13 9 100.0 0.0017 0.0017 0.0017 0.2 2.0 
14 9 100.0 0.0018 0.0018 0.0018 0.2 2.0 
15 13 100.0 0.0010 0.0010 0.0010 0.2 2.0 
16 10 100.0 0,0077 0.0083 0.0080 1.1 11.0 
17 10 100.0 0 .0011 0 .0011 0. 0011 0.3 3.0 
18 13 100.0 0.0015 0.0015 0.0015 0.2 2.0 
19 11 100.0 0.0061 0.0063 0.0062 0.3 3.0 
20 12 100.0 0.0066 0.0070 0.0068 0.2 2.0 
a see Appendix s. 
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APPENDIX J: TYLOSIN TARTRATE RELEASE-EXPERIMENT 33B 
Sample Regres- Total Weight Weight Average Amount of Amount of 
number sion volume of of weight tylosin tylosin · 
line of peak peak of peak tartrate tartrate 
dataa sample #1 #2 (gm) in in total 
(ul) (gm) (gm) 10 ul sample 
(ug) volume 
(ug) 
1 19 480.0 0.0745 0.0723 0.0734 5.0 240.0 
2 No spot developed on the TLC plate 
3 19 180.0 0.0284 0.0302 0.0293 2.1 37.8 
4 18 100.0 0.0591 0.0593 0.0592 2.9 29.0 
5 20 100.0 0.0204 0.0200 0.0202 1.0 10.0 
6 20 100.0 0.0502 0.0492 0.0497 2.7 27.0 
7 20 100.0 0.0105 0.0085 0.0095 0.4 4.0 
8 20 100.0 0.0268 0.0256 0.0262 1.3 13.0 
9 20 100.0 0.0010 0.0010 0.0010 0.2 2.0 
10 21 100.0 0.0008 0.0008 0.0008 0.2 2.0 
11 21 100.0 0.0012 0.0014 0.0013 0.2 2.0 
12 21 100.0 0.0031 0.0039 0.0035 0.3 3.0 
13 21 100.0 0 .0013 0. 0011 0.0012 0.2 2.0 
14 21 100.0 0.0016 0.0014 0.0015 0.2 2.0 
15 22 100.0 0.0010 0.0008 0.0009 0.2 2.0 
l& 18 100.0 0.0435 0.0431 0.0433 2.1 21.0 
17 22 100.0 0.0039 0.0041 0.0040 0.5 5.0 
18 22 100.0 0.0022 0.0020 0.0021 0.3 3.0 
19 22 100.0 0.0018 0.0022 0.0020 0.2 2.0 
20 22 100.0 0.0013 0.0013 0.0013 0.2 2.0 
a See Appendix s. 
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APPENDIX K: TYLOSIN TARTRATE RELEASE-EXPERIMENT 33C 
Sample Regres- Total Weight Weight Average Amount of Amount.of 
number sion volume of of weight tylosin tylosin 
line of peak peak of peak tartrate tartrate 
dataa sample #1 #2 (gm) in in total 
(ul) (gm) (gm) 10 ul sample 
(ug) volume 
(ug) 
1 20 580.0 0.0052 'o. oos2 0.0052 2.8 162.4 
2 19 180.0 0.0359 0.0341 0.0350 2.4 43.2 
3 22 100.0 0.0144 0.0134 0.0139 1.5 15.0 
4 13 100.0 0.1111 0.0105 0.0108 0.9 9.0 
5 23 100.0 0.0085 0.0087 0.0086 0.8 8.0 
6 23 100.0 0.0051 0.0053 0.0052 0.5 5.0 
7 23 100.0 0.0045 0.0049 0.0047 0.5 5.0 
8 23 100.0 0.0094 0.0082 0.0088 0.8 8.0 
9 23 100.0 0.0029 0.0029 0.0029 0.4 4.0 
10 24 100.0 0.0026 0.0024 0.0025 0.2 2.0 
11 24 100.0 0.0033 0.0031 0.0032 0.2 2.0 
12 24 100.0 0.0061 0.0067 0.0064 0.4 4.0 
13 24 100.0 0.0028 0.0028 0.0028 0.2 2.0 
14 100.0 No spot developed on the TLC plate 
15 24 100.0 0.0010 0.0012 0 .0011 0.2 2.0 
16 25 100.0 0.0062 0.0060 0.0061 0.3 3.0 
17 25 100.0 0.0018 0.0018 0.0018 0.2 2.0 
18 25 100.0 0.0016 0.0012 0.0014 0.2 2.0 
19 25 100.0 0.0015 0 .0013 0.0014 0.2 2.0 
20 25 100.0 0.0055 0.0055 0.0055 0.3 3.0 
a See Appendix s. 
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APPENDIX L: TYLOSIN TARTRATE RELEASE-EXPERIMENT 330 
Sample Regres- Total Weight Weight Average Amount of Amount of 
number sion volume of of weight tylosin tylosin 
line of peak peak of peak tartrate tartrate 
dataa sample #1 #2 (gm) in in total 
(ul) (gm) (gm) 10 ul sample 
(ug) volume 
(ug) 
1 19 180.0 0.0334 0.0358 0.0346 2.4 43.2 
2 27 180.0 0.0297 0.0303 0.0300 1. 7 30.6 
3 27 100.0 0 .0171 0.0147 0.0159 0.9 9.0 
4 27 100.0 0.0210 0.0196 0.0203 1.2 12.0 
5 25 100.0 0.0046 0.0058 0.0052 0.3 3.0 
6 26 100.0 0.0022 0.0022 0.0022 0.2 2.0 
7 26 100.0 0.0030 0.0032 0.0031 0.2 2.0 
8 26 100.0 0.0084 0.0098 0.0091 0.5 5.0 
9 26 100.0 0.0044 0.0044 0.0044 0.3 3.0 
10 26 100.0 0.0014 0.0014 0.0014 0.2 2.0 
11 100.0 No spot developed on the TLC plate 
12 19 100.0 0.0048 0.0044 0.0046 0.4 4.0 
13 29 100.0 0.0055 0.0055 0.0055 0.2 2.0 
14 29 100.0 0.0072 0.0068 0.0070 0.3 3.0 
15 29 100.0 0.0043 0.0039 0.0041 0.2 2.0 
16 29 100.0 0. 0118 0.0122 0.0120 0.5 5.0 
17 28 100.0 0.0027 0.0027 0.0027 0.2 2.0 
18 28 100.0 0.0008 0.0008 0.0008 0.2 2.0 
19 28 100.0 0.0016 0.0016 0.0016 0.2 2.0 
20 28 100.0 0.0055 0.0055 0.0055 0.3 3.0 
asee Appendix s. 
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APPENDIX M: TYLOSIN TARTRATE RELEASE-EXPERIMENT 33E 
Sample Regres- Total Weight Weight Average Amount of Amount of 
number sion volume of of weight tylosin tylosin 
line of peak peak of peak tartrate tartrate 
dataa sample #1 #2 {gm) in in total 
(ul) {gm) (gm) 10 ul sample 
(ug) volume 
(ug). 
1 30 1180. 0 0.0392 0.0412 0.0402 4.1 483.8 
2 30 290.0 0.0426 0.0446 0.0436 4.3 124.7 
3 30 190.0 0.0137 0.0133 0.0135 1.2 22.8 
4 30 190.0 0.0180 0.0168 0.0174 1.6 30.4 
5 28 100.0 0.0138 0.0144 0.0141 0.7 7.0 
6 100.0 No spot developed on the TLC plate 
7 100.0 No spot developed on the TLC plate 
8 31 100.0 0.0046 0.0052 0.0049 0.6 6.0 
9 31 100.0 0.0021 0.0021 0.0021 0 .4 4.0 
10 31 100.0 0.0102 0.0100 o·.0101 1.1 11.0 
11' 32 100.0 0.0087 0.0089 0.0088 0.7 7.0 
12 32 100.0 0.0160 0.0150 0.0155 1.2 12.0 
13 32 100.0 0.0069 0.0061 0.0065 0.6 6.0 
14 32 100.0 0.0024 0.0026 0.0025 0.3 3.0 
15 32 100.0 0.0032 0.0032 0.0032 0.4 4.0 
16 33 100.0 0.0091 0.0093 0.0092 0.7 7.0 
17 33 100.0 0.0012 0.0018 0.0016 0.2 2.0 
18 33 100.0 0.0010 0.0010 0.0010 0.2 2.0 
19 33 100.0 0.0011 0 .0011 0. 0011 0.2 2.0 
20 33 100.0 0.0007 0.0009 0.0008 0.2 2.0 
asee Appendix s. 
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APPENDIX N: TYLOSIN TARTRATE RELEASE-EXPERIMENT 34A 
Sample Regres- Total Weight Weight Average Amount of Amount of 
number sion volume of of weight tylosin tylosin 
line of peak peak of peak tartrate tartrate 
dataa sample #1 #2 (gm) in in total 
(ul) (gm) (gm) 10 ul sample 
(ug) volume 
(ug) 
1 34 48090.0 0.0297 0.0283 0.0290 1. 7 8175.3 
2 35 48090.0 0.0157 0.0149 0.0153 1.5 7213.5 
3 36 16030.0 0.0182 0.0192 0.0187 2.4 3847.2 
4 37 48090.0 0.0205 0.0197 0.0201 1.6 7694.4 
5 38 16030.0 0.0046 0.0036 0.0041 1.8 2885.4 
6 39 1290.0 0.0575 0.0585 0.0580 2.7 348.3 
7 39 2580.0 0.0881 0.0869 0.0875 4.1 1057.8 
8 39 290.0 0.0664 0.0622 0.0643 3.0 87.0 
9 39 190.0 0.0530 0.0516 0.0523 2.4 45.6 
1.0 39 290.0 0.0700 0.0672 0,0686 3.2 92.8 
11 40 290.0 0.0244 0.0254 0.0249 1.9 55.1 . 
12 40 100.0 0.0219 0.0223 0.0221 1. 7 17.0 
13 40 100.0 0.0199 0.0197 0.0198 1.5 i.5 ~ o 
.14 40 100.0 0.0214 0.0224 0.02i.9 1. 7 17.0 
15 40 100.0 0.0206 0.0206 0.0206 1.6 16.b 
16 41 290.0 0.0400 0.0394 0.0397 3.1 89.9 
17 41 100.0 0.0084 0.0074 0.0079 0.7 7.0 
18 41 100.0 0.0040 0.0042 0.0041 0.4 4.0 
19 41 190.0 0.0136 0.0128 0.0132 1.1 20.9 
20 41 2~0.0 0.0170 0.0178 0.0174 1.4 40.6 
a see Appendix s. 
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APPENDIX 0: TYLOSIN TARTRATE RELEASE-EXPERIMENT 348 
Sample Regres- Total Weight Weight Average Amount of Amount of 
number sion volume of of weight tylosin tylosin 
line of peak peak of peak tartrate tartrate 
data a sample #1 #2 (gm) in in total 
(ul) (gm) (gm) 10 ul sample 
(ug) volume 
(ug) 
1 42 48090.0 0.0169 0.0165 0.0167 2.0 9618.0 
2 43 48090.0 0.0241 0.0233 0.0237 1.2 5770. 8 
3 44 48090.0 0.0261 0.0263 0.0262 2.4 11541.6 
4 45 4360.0 0.0227 0.0333 0.0330 3.4 1482.4 
5 47 2360.0 0.0280 0 .0272 0.0286 3.1 731.6 
6 34 1090.0 0.0902 0.0918 0.0910 4.8 523.2 
7 34 1090.0 0.0433 0.0459 0.0446 2.4 261.6 
8 34 1090.0 0.0884 0.0912 0.0898 4.7 512.3 
9 34 380.0 0.0603 0.0617 0.0610 3.2 121.6 
10 34 380.0 0.0508 0.0490 0.0499 2.7 102.6 
11 46 1160.0 0.0191 0.0197 0.0194 4.7 545.2 
12 46 3270.0 0.0183 0.0179 0.0181 2.5 817.5 
13 46 290.0 0.0225 0.0235 0.0230 3.2 92.8 
14 46 190.0 0.0191 0.0185 0.0188 2.6 49.4 
15 46 190.0 0.0128 0.0124 0.0126 1.8 34.2 
16 49 380.0 0.0373 0.0383 0.0378 3.1 111.i'r 
17 49 380.0 0.0360 0.0344 0.0352 2.7 102.6 
18 49 190.0 0.0604 0.0588 0.0596 4.8 91.2 
19 49 190.0 0.0480 0.0498 0.0489 4.0 76.0 
20 49 190.0 0.0158 0.0166 0.0162 1.4 26.6 
asee Appendix s. 
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APPENDIX P: TYLOSIN TARTRATE RELEASE-EXPERIMENT 34C 
Sample Regres- Total Weight Weight Average Amount of Amount of 
number sion volume of of weight tylosin tylosin 
line of peak peak of peak tartrate tartrate 
data a sample Ill 112 (gm) in in total 
(ul) (gm) (gm) 10 ul sample 
(ug) volume 
(ug) 
1 38 300.0 0.0043 0.0047 0.0045 0.7 21.0 
2 38 300.0 0.0202 0.0188 0.0195 2.9 87.0 
3 38 100.0 0.0025 0.0025 0.0025 1.2 12.0 
4 38 100.0 0.0020 0.0020 0.0020 0.6 6.0 
5 38 100.0 0.0039 0. 0017 0.0028 0.8 8.0 
6 44 100.0 0.0035 0.0033 0.0034 0.4 4.0 
7 44 100.0 0.0014 0.0014 0.0014 0.2 2.0 
8 44 100.0 0.0065 0.0063 0.0064 0.7 7.0 
9 44 100.0 0 .0049. 0.0043 0.0046 0.5 5.0 
10 44 100.0 0.0025 0.0021 0.0023 0.5 5.0 
11 36 100.0 0.0072 0.0076 0.0074 0.3 3.0 
12 36 100.0 0.0187 0.0185 0.0186 0.8 8.0 
13 36 100.0 0.0097 0.0087 0.0092 0.4 4.0 
14 36 100.0 0.0412 0.0412 0.0412 1.9 19.0 
15 36 100.0 0.0352 0.0334 0.0343 1.5 15.0 
16 48 190.0 0.0538 0.0526 0.0532 1.2 22.8 
17 48 190.0 0 .0378 0.0360 0.0369 5.0 95.0 
18 48 380.0 0.0253 0.0241 0.0247 3.3 125.4 
19 48 380.0 0.0231 0.0243 0.0237 3.1 117 .8 
20 37 1180. 0 0.0412 0.0402 0.0407 3.6 424.8 
asee Appendix s. 
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APPENDIX Q: TYLOSIN TARTRATE RELEASE-EXPERIMENT 340 
Sample Regres- Total Weight Weight Average Amount of Amount of 
number sion volume of of weight tylosin tylosin 
line of peak peak of peak tartrate tartrate 
data 8 sample #1 #2 (gm) in in total 
(ul) (gm) (gm) 10 ul sample 
(ug) volume 
(ug) 
1 42 300.0 0.0034 0.0024 0.0029 3.9 117 .o 
2 50 100.0 0.0060 0.0064 0.0062 0.3 3.0 
3 51 100.0 0.0154 0.0134 0.0144 1.0 10.0 
4 42 100.0 0.0066 0.0062 0.0064 1.6 16.0 
5 42 100.0 0.0026 0.0026 0.0026 0.6 6.0 
6 43 100.0 0.0329 0.0337 0.0333 1.6 16.0 
7 43 100.0 0.0343 0.0367 0.0355 1.8 18.0 
8 43 200.0 0.0573 0.0567 0.0570 2.9 58.0 
9 43 100.0 0.0764 0.0768 0.0766 3.9 39.0 
10 43 190.0 0.0541 0.0549 0.0545 2.7 51.3 
11· 45 100.0 0.0259 0.0245 0.0252 2.6 26.0 
12 45 290.0 0.0387 0.0373 0.0380 3.9 113 .1 
13 45 290.0 0.0129 0.0121 0.0125 1.4 40.6 
14 45 290.0 0 .0110 0.0108 0.0109 1.2 34.8 
15 45 290.0 0.0188 0.0182 0.0185 2.0 58.0 
16 48 1180. 0 0.0206 0.0190 0.0198 2.6 306.8 
17 47 290.0 0.0327 0.0339 0.0333 3.5 101.5 
18 47 290.0 0.0252 0.0260 0.0256 2.7 78.3 
19 47 290.0 0.0148 0.0164 0.0156 1. 7 49.3 
20 47 580.0 0.0286 0.0280 0.0283 3.0 174.0 
8 See Appendix s. 
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APPENDIX R: TYLOSIN TARTRATE RELEASE-EXPERIMENT 34E 
Sample Regres- Total Weight Weight Average Amount of Amount of 
number sion volume of of weight tylosin: tylosin 
line of peak peak of peak tartrate tartrate 
data a sample #1 #2 (gm) in in total 
(ul) (gm) (gm) 10 ul sample 
(ug) volume 
(ug) 
1 so 48090.0 0.0255 0.0297 0.0276 2.1 10098.9 
2 50 48090.0 0.0212 0.0224 0.0218 1.6 7694.4 
3 50 7160. 0 0.0438 0.0458 0.0448 3.6 2577. 6 
4 50 16030.0 0.0087' 0 .0091. 0,0089 1.5 2404.5 
5 50 1690.0 0.0438 0.0452 0.0445 3.6 608".4 
6 51 1690.0 0.0703 0.0657 0.0680 4.4 743.6 
7 51 590.0 0.0344 0.0364 0.0354 2.3 135.7 
8 51 100.0 0.0076 0.0060 0.0068 0.5 5.0 
9 51 590.0 0.0593 0.0617 0.0605 3.9 230.1 
10 51 190.0 0.0474 0.0482 0.0478 3.1 58.9 
11 53 290.0 0.0070 0.0080 0.0075 1.4 40.6 
12 53 1080.0 0. 0371 0.0359 0.0365 5.0 540.0 
13 53 1080.0 0.0256 0.0250 0.0253 3.7 399.6 
14 53 290.0 0.0073 0.0073 0.0073 1.3 37,7: 
15 53 590.0 0.0091 0.0091 0.0091 1.9 112 .1 
16 52 590.0 0.0386 0.0366 0.0376 2.5 147.5 
17 52 290.0 0.0032 0.0034 0.0033 0.6 17.4 
18 52 290.0 0.0034 0.0034 0.0034 0.6 17 .4 
19 52 290.0 0.0092 0.0088 0.0090 1.2 34.8. 
20 52 290.0 0.0054 0.0062 0.0058 0.8 23.2 
a See Appendix s. 
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APPENDIX S: REGRESSION LINE DATA FOR THE TYLOSIN TARTRATE.RELEASE 
EXPERIMENT 
Regression Amount of Weight of Weight of Average weight 
line tylosin peak Ill peak 112 of peak 
data tartrate (gm) (gm) (gm) 
(ug) 
1 0.4 0.0072 0.0066 0.0069 
1 0.8 0.0133 0.0137 0.0135 
1 1.0 0.0188 0.0204 0.0196 
1 2.0 0.0362 0.0376 0.0369 
1 3.0 0.0485 0.0523 0 .. 0504 
2 0.4 0.0048 0.0044 0.0046 
2 0.8 0. 0110 0.0122 0.0166 
2 1.0 0.0170 0.0160 0.0165 
2 2.0 0.0296 0.0306 0.0301 
2 3.0 0.0380 0.0404 0.0392 
3 0.2 0.0041 0.0039 0.0040 
3 0.5 0.0089 0.0093 0.0091 
3 0.8 0.0149 0.0147 0.0148 
3 1.0 0.0230 0.0234 0.0232 
3 2.o 0.0380 0.0382 0.0381 
4 0.2 0.0024 0.0016 0.0020 
4 0.5 0.0046 0.0046 0.0046 
4 0.8 0.0088 0.0090 0.0089 
4 1.0 0.0128 0.0122 0.0125 
4 2.0 0.0249 0.0241 0.0245 
5 0.4 0.0070 0.0068 0.0069 
5 0.8 0.0150 0.0146 0.0148 
5 1.0 0.0195 0.0197 0.0196 
5 2.0 0.0372 0.0352 0.0362 
5 3.0 0 .. 0483 0.0453 0.0468 
6 0.2 0.0019 0.0019 0.0019 
6 0.5 0.0046 0.0054 0.0050 
6 0.8 0.0068 0.0074 0.0071 
6 1.0 0.0125 0.0125 0.0125 
6 2.0 0.0264 0.0260 0.0262 
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Regression Amount of Weight of Weight of Average weight 
line tylosin peak Ill peak #2 of peak. 
data tartrate (gm) (gm) (gm) 
(ug) 
7 0.4 0.0100 0.0086 0.0093 
7 0.8 0.0162 0.0158 0.0160 
7 1.0 0.0209 0.0225 0.0217 
7 2.0 0. 0377 0.0389 0.0383 
7 3.0 0.0539 0.0539 0.0539 
8 0.2 0.0043 0.0037 0.0040 
8 0.5 0.0123 0.0095 0.0109 
8 0.8 0.0172 0.0162 0.0167 
8 1.0 0.0205 0.0209 0.0207 
8 2.0 0.0434 0.0426 0.0430 
9 0.2 0.0024 0.0024 0.0024 
9 0.6 0.0046 0.0048 0.0047 
9 0.8 0.0075 0.0073 0.0074 
9 1.0 0.0104 0.0094 0.0099 
9 2.0 0.0181 0.0181 0.0181 
10 0.2 0.0010 0.0010 0.0010 
10 0.6 0.0027 0.0027 0.0027 
10 0.8 0.0054 0.0054 0.0054 
10 1.0 0.0071 0.0073 0.0072 
10 2.0 0.0163 0.0163 0.0163 
11 0.4 0.0083 0.0083 0.0083 
11 0.8 0.0158 0.0148 0.0153 
11 1.0 0.0196 0.0214 0.0205 
11 2.0 0.0419 0.0403 0. 0411 
11 3.0 0.0569 0.0531 0.0550 
12 0.2 0.0055 0.0057 0.0056 
12 0.6 0.0126 0.0144 0.0135 
12 1.0 0.0232 0.0234 0.0233 
12 2.0 0.0425 0.0445 0.0435 
12 3.0 0.0619 0.0539 0.0579 
13 0.2 0.0034 0.0030 0.0032 
13 0.6 0.0078 0.0074 0.0076 
13 0.8 0.0128 0.0124 0.0126 
13 1.0 0.0176 0.0164 0.0170 
13 2.0 0.0300 0.0290 0.0295 
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Regression Amount of Weight of Weight of Average weight 
line. tylosin peak #1 peak #2 of peak. 
data tartrate (gm) (gm) (gm) 
(ug) 
14 0.2 0.0037 0.0027 0.0032 
14 0.6 0.0100 0.0108 0.0104 
14 1.0 0.0180 0.0188 0.0184 
14 2.0 0.0337 0.0325 0.0331 
14 3.0 0.0455 0.0447 0.0451 
15 0.2 0.0023 0.0023 0.0023 
15 0.6 0 .0096 0.0086 0.0091 
15 0.8 0.0136 0.0126 0.0131 
15 1.0 0.0174 0.0180 o .0177 
15 2.0 0.0310 0.0294 0.0302 
16 0.2 0.0026 0.0028 0.0027 
16 0.6 0.0087 0.0083 0;0085 
16 1.0 0.0172 0.0180 0.0176 
16 . 2.0 0.0339 0.0343 0.0341 
16 3.0 0.0526 0.0456 0.0491 
17 0.2 0.0022 0.0028 0.0025 
17 0.6 0.0072 0.0070 o .oon 
17 1.0 0.0139 0.0147 0.0143 
17 2.0 0.0308 0.0290 0.0299 
17 3.0 0.0476 0.0450 0.0463 
18 0.2 0.0045 0.0049 0.0047 
18 0.6 0.0102 0 .0110 0.0106 
18 1.0 0.0221 0.0217 0.0219 
18 2.0 0.0418 0.0410 0.0414 
18 3.0 o .0611 0.0605 0.0608 
19 0.2 0.0023 0.0023 0.0023 
19 0.6 0.0045 0.0057 0.0051 
19 1.0 0.0136 0.0138 0.0137 
19 2.0 0.0287 0.0285 0.0286 
19 3.0 0.0443 0.0425 0.0434 
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Regression Amount of Weight of Weight of Average weight 
line tylosin peak #1 peak #2 of peak 
data tartrate (gm) (gm) (gm) 
(ug) 
20 0.2 0.0045. 0.0041 0.0043 
20 0.6 0.0122 0.0128 0.0125 
20 1.0 0.0216 0.0214 0.0215 
20 2.0 0.0398 0.0390 0.0394 
20 3.0 0.0548 0.0532 0.0540 
21 0.2 0.0012 0.0012 0.0012 
21 0.6 0.0078 0.0070 0.0074 
21 1.0 0.0134 0.0134 0.0134 
21 2.0 0.0261 0.0247 0.0254 
21 3.0 0.0413 0.0395 0.0404 
22 0.2 0.0013 0.0015 0.0014 
22 0.6 0.0067 0.0059 0.0063 
22 0.8 0.0073 0.0061 0.0067 
22 1.0 0.0079 0.0085 0.0082 
22 2.0 0.0186 0.0178 0.0182 
23 0.2 . 0.0022 0.0018 0.0020 
23 0.6 0.0053 0.0045 0.0049 
23 0.8 0.0083 0.0081 0.0082 
23 1.0 0 .0115 0.0155 0. 0115 
23 2.0 0.0285 0.0271 0.0278 
24 0.2 0.0042 0.0042 0.0042 
24 0.6 0. 0112 0.0100 0.0106 
24 0.8 0.0162 0.0160 0.0161 
24 1.0 0.0225 0.0229 0 .02t1 
24 2.0 0.0448 0.0448 0.0448 
25 0.2 0.0037 0.0035 0.0036 
25 0.6 0. 0114 0. 0118 0 .0116 
25 0.8 0.0156 0.0160 0.0158 
25 1.0 0.0201 0.0203 0.0202 
25 2.0 0.0400 0.0428 0.0414 
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Regression Amount of Weight of Weight of Average weight 
line tylosin peak #1 peak #2 of peak 
data tartrate {gm) {gm) {gm) 
(ug) 
26 0.2 0.0032 0.0036 0.0034 
26 0.6 0.0106 0.0100 0.0103 
26 0.8 0.0156 0.0160 0.0158 
26 1.0 0.0204 0.0220 0.0212 
26 2.0 0.0408 0.0394 0.0401 
27 0.2 0.0029 0.0027 0.0028 
27 0.6 0.0076 0.0074 0.0075 
27 1.0 0.0174 0.0170 0.0172 
27 2.0 0.0430 0.0400 0.0415 
27 3.0 0.0495 0.0527 0. 0511 
28 0.2 0.0032 0.0034 0.0033 
28 0.6 0.0093 0.0095 0:0094 
28 1.0 0.0222 0.0210 0.0216 
28 2.0 0.0454 0.0462 0.0458 
28 3.0 0.0639 0.0631 0.0635 
29 0.2 0.0041 0.0041 0.0041 
29 0.6 0 .0113 0. 0113 0.0113 
29 1.0 0.0248 0.0236 0.0242 
29 2.0 0.0480 0.0476 0.0478 
29 3.0 0.0656 0.0588 0.0622 
30 0.6 0.0096 0.0088 0.0092 
30 1.0 0.0138 0.0148 0.0143 
30 2.0 0.0212 0.0212 0.0212 
30 3.0 0.0298 0.0298 0.0298 
30 4.0 0.0419 0.0413 0.0416 
31 0.2 0.0012 0.0012 0.0012 
31 0.6 0.0042 0.0046 0.0044 
31 1.0 0.0087 0.0087 o .:0087 
31 2.0 0.0189 0.0191 0.0190 
31 3.0 0.0318 0.0288 0.0303 
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Regression Amount of Weight of Weight of Average weight 
line tylosin peak 111 peak #2 of peak 
data tartrate (gm) (gm) (gm) 
(ug) 
32 0.2 0.0021 0.0021 0.0021 
32 0.6 0.0055 0.0055 0.0055 
32 1.0 0.0120 0.0120 0.0120 
32 2.0 0.0288 0.0304 0.0296 
32 3.0 0.0456 0.0438 0.0447 
33 0.2 0.0020 0.0020 0.0020 
33 0.6 0 .0077 0.0073 0.0075 
33 1.0 0.0146 0.0136 0.0141 
33 2.0 0.0315 0.0293 0.0304 
33 3.0 0.0482 0.0492 0.0487 
34 1.0 0.0172 00170 0. 0171 
34 2.0 0.0368 0.0374 0 .0371 
34 3.0 0.0528 0.0546 0.0537 
34 4.0 0.0720 0.0744 0.0732 
34 5.0 0.0994 0.0976 0.0985 
35 1.0 0.0106 0. 0116 0. 0111 
35 2.0 0.0213 0.0235 0.0224 
35 3.0 0.0346 0.0332 0.0339 
35 4.0 0.0442 0.0440 0.0441 
35 5.0 0.0656 0.0654 0.0655 
36 0.2 0.0044 0.0040 0.0042 
36 0.6 0 .0118 0. 0118 0.0118 
36 1.0 0.0250 0.0250 0.0250 
36 2.0 0.0478 0.0466 0.0472 
36 3.0 0.0642 0.0646 0.0644 
37 0.6 0.0072 0.0064 0.0068 
37 1.0 0.0134 0.0140 0.0137 
37 2.0 0.0282 0.0290 0.0286 
37 3.0 0.0350 0.0364 0.0357 
37 4.0 0.0428 0.0430 0.0429 
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Regl:"ession Amount of Weight of Weight of Avenge weight 
line tylosin peak #1 peak #2 of peak 
data tal:"ti-ate {gm} (gm) (gm) 
(ug} 
38 0.2 0.0025 0.0021 0.0023 
38 0.6 0.0035 0.0033 0.0034 
38 1.0 0.0081 0.0087 0.0084 
38 2.0 0.0164 0.0182 0.0173 
38 3.0 0.0230 0.0232 0.0231 
39 1.0 0.0241 0.0245 0.0243 
39 2.0 0.0456 0.0494 0.0460 
39 3.0 0.0634 O.OG60 0.0641 
39 4.0 0.0820 0.0832 0.0826 
39 5.0 0.1078 0.1088 0.1083 
40 0.2 0.0028 0.0024 0.0026 
40 0.6 0.0063 0.0055 0.0059 
40 1.0 0.0144 0.0134 0.0139 
40 2.0 0.0274 0.0282 0.0278 
40 3.0 0.0399 0.0387 0.0393 
41 0.2 0.0027 0.0025 0.0026 
41 0.6 0.0058 0.0062 0.0060 
41 1.0 0.0129 0.0121 0.0125 
41 2.0 0.0243 0.0273 0.0258 
41 3.0 0.0394 0.0388 0.0391 
42 0.2 0.0016 0.0016 0.0016 
42 0.6 0.0050 0.0046 0.0048 
42 1.0 0.0079 0.0075 0.0077 
42 2.0 0. 0171 0.0165 0.0168 
42 3.0 0.0265 0.0237 0.0251 
43 0.2 0.0041 0.0049 0.0045 
43 0.6 0.0133 0.0109 0 .0111 
43 1.0 0.0230 0.0220 0.0225 
43 2.0 0.0436 0.0444 0.0440 
43 3.0 0.0570 0.0576 0.0573 
159 
Regression Amount of Weight of Weight of Average weight 
line tylosin peak #1 peak #2 of peak 
data tartrate (gm) (gm) (gm) 
(ug) 
44 0.2 0.0012 0.0012 0.0012 
44 0.4 0.0039 0.0041 0.0040 
44 1.0 0.0106 0. 0114 0. 0110 
44 2.0 0.0255 0.0245 0.0250 
44 3.0 0.0300 0.0324 0.0312 
45 0.4 0.0024 0.0026 0.0025 
45 1.0 0.0100 0.0088 0.0094 
45 2.0 0.0190 0.0202 0.0196 
45 3.0 0.0268 0.0282 0.0275 
45 4.0 0.0384 0.0402 0.0393 
46 0.2 0.0012 0.0012 0.0012 
46 0.6 0.0034 0.0032 0.0033 
46 1.0 0.0066 0.0054 0.0065 
46 2.0 0.0137 0.0139 0.0138 
46 3.0 0 .0214 0.0224 0.0219 
47 1.0 0.0083 0.0087 0.0085 
47 2.0 0.0208 0. 0'202 0.0205 
47 3.0 0.0265 0.0279 0.0272 
47 4.0 0.0371 0.0365 0.0368 
47 5.0 0.0472 0.0478 0.0475 
48 0.4 0.0030 0.0030 0.0030 
48 1.0 0.0090 0 .009.0 0.0090 
48 2.0 0.0174 0.0172 0.0173 
48 3.0 0.0202 0.0228 0.0215 
48 4.0 0.0309 0.0289 0.0299 
49 0.2 0.0036 0.0030 0.0033 
49 0.6 0.0042 0.0050 0.0046 
49 1.0 0.0102 0.0108 0.0105 
49 2.0 0.0249 0.0249 0.0249 
49 3.0 0.0366 0.0364 0.0365 
160 . 
Regression Amount of Weight of Weight of Average weight 
line tylosin peak #1 peak #2 of peak 
data tartrate (gm) (gm) (gm) 
(ug) 
50 0.4 0. 0071 0.0059 0.0065 
50 1.0 0.0140 0.0152 0.0146 
50 2.0 0.0284 0.0274 o·.0279 
50 3.0 0.0361 .0.0375 O'. 0368 
50 4.0 0.0494 0.0464 0.0479 
51 0.4 0.0050 0.0046 0.0048 
51 1.0 0.0143 0.0155 0.0149 
51 2.0 0.0312 0.0328 0.0320 
51 3.0 0.0468 0.0454 0.0461 
51 4.0 0 .06.09 0.0617 0.0613 
52 0.4 0.0079 0.0065 0.0072 
52 1.0 0.0130 0.0132 0.0131 
52 2.0 0.0308 0.0300 0.0304 
52 3.0 0.0434 0.0410 0. 0'422 
52 4.0 0.0618 0.0628 0.0623 
53 0.4 0.0041 0.0043 0.0042 
53 1.0 0.0067 0 .0071 0.0069 
53 2.0 0.0096 0.0092 o .oog:4 
53 3.0 0 .0115 0.0115 0 .0115 
53 4.0 0.0180 0.0168 0.0174 
